

01.08.2023 .

	(/)		400
A06.30.002.001			1000
	(, , ,)		200
	(, ,)		350
A06.30.002.002			1000
A06.30.002			500
B01.039.001	(,) -		1200
B01.039.002	(,) -		1100
A06.23.004	/		2600
A06.23.005.006	/		8700
A06.08.007	,		2600
A06.08.007.004			8700
A06.25.003			2600
A06.25.003.002			8700
A06.26.006			2600
A06.26.006.001			8700
A06.23.004.007			8700
A06.08.007.002			8700
			8700
A06.08.009.002			8700
A06.09.005			2600
A06.09.005.002			8700
A06.11.004			2600
A06.11.004.001			8700
A06.30.005			3500
A06.30.005.003			8700
A06.28.009			3500
A06.28.009.001			8700
A06.30.007			8700
A06.30.007.002			8700

A06.30.005.001						8700
-	()				
A06.03.021.001						2600
A06.03.021.002						8700
A06.03.021.001		-	2	(2		3600
,2	,2)				
A06.03.021.002		-	2	(2		9700
,2	,2)				
A06.03.036.001						2600
A06.03.036.002						8700
A06.03.058		()			2600
A06.03.058.003		()			8700
A06.03.062						2600
A06.04.020		-				2600
A06.04.017						2600
						2600
						8700
A06.12.052	-					8700
A06.12.053	-					8700
A06.12.050	-					8700
A06.12.054	-					8700
A06.12.055	-					8700
A06.12.057	-					8700
A06.12.058	-					8700
A06.12.001.001	-					8700
A06.12.001.002	-					8700
A06.10.009		()			3500
A06.10.006.001	-					8700
A06.10.006.001						8700
-						
A05.23.009						3100
A05.23.009.001						7100
A05.12.004		()			3100
A05.12.005		()			3100
						7100
						7100
A05.22.002.001						6500
A05.26.008.001						7100
A05.08.001						3100
A05.26.008						3100
A05.22.002						3100
A05.04.001	-					5000

A05.30.008			3100
A05.04.001	-		3100
A05.30.008			3100
A05.03.002			3100
A05.03.002			3100
A05.03.002			3100
A05.03.002.001			7100
A05.30.008.001			7100
A05.03.002.001			7100
A05.03.002.001			7100
A05.23.009.010	()		3100
A05.23.009.011		()	7100
		()	14000
A05.30.005			4000
A05.30.007			4000
A05.30.005.001			7100
A05.30.007.001			7100
A05.22.001	-		4000
A05.22.001.001	-		7100
A05.14.002			7100
A05.15.001			3500
A05.15.002			4000
A05.28.002			3100
A05.30.004.001			7100
A05.30.004			4000
A05.21.001			4000
	()+		7000
A05.21.001.001	c		7100
A05.30.004.001			7100
A05.30.004			4000
A05.30.004	()	(, , , ,)	4000
A05.04.001	(, , ,)		3500
A05.30.011.002			3500
A05.30.012.002			3500
A05.30.010			4000
A05.01.002			4000
A05.01.001			7100

A05.30.010.001			7100	
A05.03.002	+	+	7000	
	+		5000	
	+		5000	
	+		5000	
	:	+	+	7000
	+	+	7000	
	+		4500	
	+		4500	
		+	5000	
A05.03.002		+	4500	
		+	4500	
	+		7000	
	+		4500	
		+	4500	
		+	5000	
A06.08.003			800	
			800	
	2		800	
A06.08.003.002			800	
A06.08.003.002			800	
A06.03.005		,	800	
A06.03.056			800	
A06.04.001		-	800	
A06.26.001			800	
A06.07.008			800	
A06.07.009			800	
A06.25.002			800	
A06.25.002.001			800	
A06.03.010			800	
	()	3	1000
A06.03.013			800	
A06.03.019			1600	
A06.03.014			1600	
A06.03.015		2	800	
		3	1000	
A06.03.017			800	
A06.03.016			1600	

A06.03.017.001			800
A06.03.017.002			800
A06.04.013	-		800
	2		800
A06.04.010			800
A06.03.028			800
A06.04.003			800
A06.03.029			800
A06.04.004			800
A06.03.026			800
A06.03.032			800
	2		800
A06.03.035	1		700
A06.03.021			800
A06.03.030			800
A06.03.027			800
A06.03.031			800
A06.03.033			700
A06.04.005			800
	2	(1)	700
	2		850
A06.03.042			850
	2		800
A06.04.012			800
A06.03.053	2		800
			800
A06.03.050			800
			700
		2	1600
A06.03.036			800
A06.03.048			800
A06.03.054			800
A06.03.055	1		700
A06.04.011			800
A06.03.043			800
A06.03.045			800
A06.03.046			800
A06.03.049			800
A06.03.051			800
A06.03.052	1		800
A06.03.053.001			800
A06.30.004.001			700

									3000
A06.28.001									800
	2								800
A06.28.002									3100
		1		()			700
		2							850
A06.03.023			()			800
A06.03.024									800
A06.04.014			-						800
A06.03.022									700
A06.09.007									800
			-						800
									700
		1							700
		2							800
A06.20.004									1000
A06.20.004	2								1500
	c		(1		2-)			1500
	c		(2		2-)			2500
A06.20.004.002									1500
A06.20.008									1000
B01.023.001	(,)	-					1200
B01.023.002	(,)	-					1100
B01.023.001	(,)						2500
	(-)						
B01.023.001	(,)	-	()	60		2300
B01.023.002	(,)	-	()	30		2100
A11.02.002	(1)							2500
A22.30.015	(1)							1000
A11.02.002									29900
A25.24.001.002									19500
A25.24.001.002									8900
A11.01.002			225	()				24000
A11.24.001									2000
A11.02.002									1500
A11.02.002									1500
A11.02.002	()							1500

B01.047.001	(,) -	1000
B01.047.002	(,) -	1100
	()	1200
	()	2500

B01.031.001	()	1200
B01.031.002	()	1100
B01.031.001	()	2000
B01.031.002	()	2000
B01.031.001		1200
B01.031.001	()	1200
B01.031.001	-1 (,)	1500
B01.031.001	()	800
B01.031.001	/ ()	700
B01.031.001	(: ,)	800
B01.031.001	18 (095/)	800
B01.031.001	095/	800
B01.031.001		800
B01.031.001	- (076/)	2000
B01.031.001	(079/)??	800

B01.029.001	(,) -	1200
B01.029.002	(,) -	1100

A02.26.015	- ()	200
A12.26.016		150
A03.26.010	()	400
A03.26.010	()	400
A02.26.015		200
A02.26.015	()	400
A02.26.015	()	200

B01.057.001	(,) -	1200
B01.057.002	(,) -	1100
B01.057.001	(,) - ()	800
B01.057.002	(,) ()	800

A16.01.012.001		1900
A16.01.012		1200
A16.01.002		1500

A16.01.002					1200
A16.01.012.001	()	()2			1800
A16.01.011	()				1000
A16.01.027					2600
A16.30.060					1800
A16.01.009	()				1500
A16.30.069	()				500
A16.01.001					1000
A11.04.005					1000
A16.01.012.001					1300
A11.30.024					1100
A16.01.012.001	()	()1			1300
A16.01.008.001					2100
A16.01.004			(700
A16.01.004			()		2000
A15.01.001					400
A15.01.002					500
A11.01.001	()				400
A16.30.076					1400
A16.01.028	()				500
A16.01.016	(0,5-1 ,1)				1300
A16.01.016	(1-3 ,1)				1500
A16.01.016	(3-5 ,1)				1900
A16.01.017			(1-3 ,1)		1300
A16.01.017			(3-5 ,1)		1500
A16.01.017			(3-5 ,1)		1900
A16.01.017			(5 ,1)		2400
					500
A16.01.018				-	1300
(, , 0,5-1 -1)					1500
A16.01.018				-	500
(, , 1-3 -1)					500
B01.003.004.005					400
B01.003.004.001					2000
A11.01.001	()				1300
A16.01.003					1900
A16.30.032			1 -3 1		-
A16.30.032			3 -5 1		1900
A16.01.018				-	1900
(, , 3 -5 1)					
A16.30.007.001					19000
A16.30.043.002					14800
A16.30.043.003					26000
A16.14.018.003					11000
A16.30.004.003			()		42300

			56400
A16.30.004.007			65000
A16.30.004.016			55000
A16.01.018			6500
(, , 5 1) -			
A16.30.001.002		-	35000
A16.30.002.002			35000
A16.30.001	()	()	23100
A16.30.002	()		20000
A16.14.009.002			35000
A16.19.018		()	15000
A16.30.032	5	1	6500
A16.30.004.004		()	46000
)			
A16.30.004.010		1	40000
A16.30.004.010		2	55000
A16.30.004.010		3	70000
A04.12.005.003		()	1500
-)	(+		2400
-)	(+		2800
			1500
A04.12.001.004		-	800
A04.12.001.004			800
A04.12.001.001			1400
A04.12.002.002			1400
A04.12.002.001			2000
A04.12.002			1900
A04.12.002.003			1000
A04.12.001			1000
	()+		2000
A04.12.014			900
A04.12.001.006		()	1800
	()+		2800
A04.12.022			1400
A04.12.001.002			700
A04.12.003			1100
A04.22.001			500
			800
A04.22.001.001			900
			800

A04.16.001	(, , , , ,)		1100
	(,) , , , , , , , ,		2000
A04.06.001			500
A04.15.001			600
A04.28.002.005			600
A04.14.001			800
A04.14.002			500
A04.14.002.001			700
A04.18.001	()		800
A04.28.002.001			800
A04.22.002			500
A04.28.001			800
A04.28.002.001			700
A04.28.002.003			500
A04.28.003			800
A04.10.002	(+)		1800
A04.01.001	()		750
A04.09.001			600
A04.28.002.003	()		1100
A04.06.002			800
A04.06.002			800
A04.06.002			800
A04.06.002	/		800
A04.06.002			800
A04.06.002			800
A04.06.002	, / , , , , ,		2000
A04.21.001			1000
	()		1200
	()+ +		1400
A04.21.001.001	+ +		1100
	+ +		1300
A04.20.002			950
			1100
A04.30.010	()		950

A04.30.001	(1000
A04.30.001.001	()	1000
A04.30.001.007	III	1500
A04.12.024.003	(1000
A04.04.001	()	700
A04.20.003	()	700
A04.20.003	()	400
A04.20.001.004	(-)	500
A04.30.001.002	4D (26 ,	2500
A04.30.001	II	1200
A04.30.001.002	3D	1350
A04.30.001.001	()	1500
A04.12.024.003	() (II-III) (1500
A04.30.001.006	-	2000
(II)		
A04.30.001.008	III	2000
A04.30.001.002	4D ,1)	3500
A04.30.001.002	3D	2000

A11.06.001.001		900
A11.20.010.003		900
A11.22.002.001		900
A11.30.024.001		900

A04.04.001	()1	900
A04.04.001	()1	700
A04.04.001	()1	800
A04.04.001	()1	800
A04.04.001	()1	800
A04.04.001	()1	800
A04.04.001	()1	600
A04.04.002	()	600

B03.037.001		500
A05.10.006		500
A02.12.002.001		1200
A05.10.008	24	2000
+	24	2200
A12.10.001	() +	750
		750

		150
		420
		590
		190
		3230
		2020
		1100
		770
		2510
	(HIV, Syphilis, Hepatitis B, C)	1400
		470
		470
	(Coronavirus disease 2019, COVID-19)	
	SARS-CoV-2 (), IgG, (Anti-SARS-CoV-2 (nucleocapsid protein), IgG, Abbott)	690
	SARS-CoV-2, IgM (anti-SARS-CoV-2, IgM)	690
	SARS-CoV-2, IgM IgG (. . . IgG - Abbott)	1290
	(S) SARS-CoV-2, IgG (), . . . (anti-SARS-CoV-2 S (spike) protein antibody, IgG, qual., including post-vaccination)	890
	SARS-CoV-2 (RBD), IgG (anti-SARS-CoV-2 (RBD) IgG avidity)	690
	SARS CoV-2 (S- , RBD), IgG, -	1290
	SARS CoV-2 (S- , RBD), IgG, Abbott	1290
	SARS-CoV-2, IgM () IgG (Anti-SARS-CoV-2, IgM/IgG)	1690
	SARS-CoV-2, IgM () IgG (Anti-SARS-CoV-2, IgM/IgG)	1690
	()	
A	IgG Helicobacter pylori (Anti-Helicobacter pylori IgG)	490
	MICROBIOCENOSIS, Screening (PCR Panel Femoflor Screen)) . (UROGENITAL TRACT)	1850
	()	
	4 : 6, 11, 16, 18+ (HPV DNA, Scrape of Urogenital Epithelial Cells, 4 Types (6, 11, 16, 18) Screening)	550
	RPR – (Syphilis RPR (Rapid Plasma Reagins), nticardiolipin est)	210
	(Fe)	190

() (Unsaturated Iron Binding Capacity, UIBC)		190
/ / (+/Potassium, Na+ /Sodium, I-/Chloride, Serum)		250
(g) (Magnesium (Mg), Serum)		230
(Ferritin)		460
- () (C-Reactive Protein, CRP)		310
() (Transferrin)		440
25-OH D (25-OH Vitamin D Total, 25(OH)D, 25-Hydroxycalciferol)		1920
HbA1 (HbA1 , Glycated Hemoglobin, GHB)		460
A09.05.023		130
(Homocysteine)		1290
(Protein Total)		150
(Albumin)		210
() (Prostate-Specific Antigen Total, PSA Total)		440
-125 (125) (Carbohydrate Antigen -125, Cancer Antigen -125)		580
SCC (SCCAg) (Squamous Cell Carcinoma Antigen, SCCA,		2260
A09.05.020		150
(Uric cid)		150
A09.05.017		150
() (Triglycerides)		190
A09.05.004		200
() (Low-Density Lipoprotein Cholesterol, LDL Cholesterol)		150
() (Cholesterol Total)		190
A09.05.021		150
(,L- , +) (Lactate Dehydrogenase, LDH)		150
() (Alkaline Phosphatase, ALP)		150
A09.05.063 (4)		350
A09.05.065 ()		330
(- ,) (Anti- thyroid peroxidase autoantibodies, Antimicrobial Antibodies, TPO Antibodies, TPOAb, Anti-TPO)		390
(3) (Free Triiodthyronine, FT3)		350
(2) (Estradiol, E2)		350
(Insulin)		490

HOMA-IR (Insulin Resistance: Fasting Glucose/Insulin, Homeostasis Model Assessment of Insulin Resistance, HOMA-IR)		670
(Prolactin)		350
() (Follicle Stimulating Hormone, FSH)		350
() (Luteinizing Hormone, LH)		350
(,) (Growth Hormone, GH)		470
A09.05.065 ()		330
(Testosterone)		350
- (-S04, Dehydroepiandrosterone sulfate, DHEA-S)		350
(2) (Estradiol, E2)		350
(Calcitonin)		860
() (Complete Urinalysis, Microscopic Examination)		230
(Nechiporenko's Urine Test)		230
() (Amylase, 24-Hour or Timed Urine)		230
: (Lipid Profile: Extended)		2640
: (Lipid Profile: Screening)		700
(Blood Group, 0)		230
- (-) (Rh-factor, Rh)		230
(Zn) (Zinc (Zn), Serum)		250
(,) (Prothrombin, rothrombin Time, PT, International Normalized Ratio, INR)		230
D- (D-Dimer)		1030
(ThinPrep®)		1200
12 JAK2 (,) (Analysis of JAK2 Exon 12 mutations (PCR qualitative))		4390
MPL (,) (Analysis of MPL gene mutations, deletions, (PCR qualitative))		4390
CALR (,) (Analysis of CALR gene mutations, deletions, insertions, PCR, qualitative)		4390

(Urine Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		800
A12.20.001		450
Total, IgE Total)	E (IgE,) (Immunoglobulin	390
B01.058.001	(,) -	1200
B01.058.002	(,) -	1100
B01.001.001	(,) -	1500
B01.001.002	(,) -	1200
B01.001.002	() -	800
A11.20.011		1500
A11.20.014		1500
A11.20.008		5400
A11.20.008.001		2900
A11.20.005		300
A11.20.002		300
A11.20.002		450
A11.20.003		800
A03.20.001		1000
A11.20.015		500
A16.20.036		2100
A08.20.004) (1400
A11.20.015		500
A14.20.002 ()		900
A16.20.036.001		7500
A16.20.061.001		40500
A16.20.061.001		35000
A16.20.038		39000
A16.20.016		39900
A16.20.017.001		34900
A16.20.004.001		30900
A16.20.003.001	-	36900
A16.20.041.001		29900
A16.20.001.001 ()		34900
A16.20.001.001 ()		37900

A16.20.003.001			30900
A16.20.010.001	()	73900
A16.20.010.001	2	(75900
A16.20.010.003	(1	74900
A16.20.010.003	(2	84900
A16.20.010	()	58900
A16.20.011.001	()	83900
A16.20.011.001	()	94900
A16.20.011.002	()	76900
A16.20.011.002	2	(87900
A16.20.063			92900
A16.20.033			35900
A16.20.012			77900
A11.20.003			1100
A03.20.003			19000
A16.20.042.003	()	60750
-			
A16.20.035.001	()	58900
A16.20.035.001	()	39900
A16.20.035.001	()	61900
A16.20.028.002			20900
A16.20.028.003			20900
A16.20.083			38900
A16.20.023			31900
A16.20.065			21900
A16.20.063.018			21900
A03.20.003			17000
A03.20.003.001	1		26900
A03.20.003.001	2		33900
A03.20.003.001	3		39900
A16.20.066			4100
A11.20.018	()	2900
A16.20.059			950
A16.20.059.001			3900
A16.20.036			5900
A16.20.091.001			2800
A11.20.008.001			2000
A11.20.008.002			2700
A16.20.006			42000
A16.20.007			28900

A16.20.098	(1)	27770
A16.20.098 +)	(2)	41000
A16.20.083		46000
A16.20.029		27770
A16.20.024		63000
A16.20.028.005	(1)	49000
A16.20.028.005	(2)	60000
A16.20.019	+	120000
A11.01.013		10200
A11.01.013		19000
A11.01.013		26900
(7 +), (Identification of Sexually Transmitted Infections (STI) Pathogens, Scrape of Urogenital Epithelial Cells)*		1350
(4 +): Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, (Identification of Sexually Transmitted Infections (STI) Pathogens, Chlamydia trachomatis DNA, Neisseria gonorrhoeae DNA, Trichomonas vaginalis DNA, Mycoplasma genitalium DNA, Human DNA)		930
+ , o 16 18 (HPV DNA, Scrape of Urogenital Epithelial Cells, 2 Types (16, 18))		350
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68))	14 :	350
() 14 : 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)		900
(Neisseria gonorrhoeae, DNA, Scrape of Urogenital Epithelial Cells)*		250
(Neisseria gonorrhoeae,), (GC, Neisseria gonorrhoeae Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		900
(Bacterial Vaginosis, BV)		1540
(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Urogenital Epithelial Cells)*		250
A08.20.017.002 (, ThinPrep®)		1200
A08.20.004		600
(; ; ; -)*		2200
(INBIOFLOR-Comprehensive Study of Microflora Composition of Urogenital Tract (UGT))		2780
(), (Antiphospholipid Syndrome, APS)		3570
(Genitourinary Tract Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*		1160
() (Vaginal Biocenosis: Bacteriophage and Antimycotic Susceptibility Testing (Gram Stain, Bacterioscopic Examination of Smear))*		1500
(The Bethesda System ? TBS) (Cytological Examination of Cervical Epithelium with Description on The Bethesda System, TBS)		570

MICROBIOCENOSIS (PCR Panel Femoflor 16))	16. (UROGENITAL TRACT	2100
		450
-) (Cytological Examination: Cervix, Pap-test)	(1000
	(Candidiasis, Screening and Typing)	920
MICROBIOCENOSIS, Screening (PCR Panel Femoflor Screen))	. (UROGENITAL TRACT	1850
MICROBIOCENOSIS (PCR Panel Femoflor 8))	8. (UROGENITAL TRACT	1480

B01.053.001	(,) -	1200
B01.053.002	(,) -	1100

A16.28.040	(1)	2100
		10000
A16.28.058		1000
A16.28.052.001		2400
A16.28.072.001		2400
A11.28.008		1600
A11.28.006.001		500
A21.21.001		550
A12.21.003		650
A15.21.001	()	1000
A03.28.002		3500
A03.28.003	()	6000
A03.28.001		5000
A16.28.077	-	5000
A11.28.012		1000
A16.21.015		2300
A16.28.013.001		1000
A06.28.007		5000
A06.28.011		5000
	()	10000

B01.015.001	(,) -	1200
B01.015.002	(,) -	1100

B01.008.003	()	1200
B01.008.004	()	1100

A11.02.002	(1)	260
A11.02.002	(1)	290
A11.01.003	.1	2999
A11.01.003	.2	4999

A11.01.003 PRP-	1	(1)		5000
A11.01.003	mesoline	() 2,5	.	2500
A11.01.003	mesoline	() 2,5	.	2500
A16.01.024		(PRX-t33)			3750
A16.01.024					2000
A16.01.024					2500
A14.01.008					3000
					2000
B01.028.001	(,)	-	1200
B01.028.002	(,)	-	1100
B01.028.002	()		-	800
A11.01.014					200
A12.25.001					1000
A11.07.004			(1500
)				
A11.08.001			(5000
)				
		()	3000
A11.25.006			(3000
)				
					350
					200
A11.08.019					600
A16.01.012	(,	,)	-
A16.08.054					1500
A16.08.010.001	()		(RadioSURG)	10000
A11.08.007					1000
					100
A03.25.003					300
A22.30.033					2200
A11.08.022	(-)	-	(1
)
					2500
A11.08.022	(-)	-	(2
)
					3500
A21.25.002					250
A11.07.022					300
			(,	800
)				
A16.01.004					400
A15.01.002					1000
					800
A16.08.006.001			(1)	2000
	,			-	2000
A12.25.006					300
					700

A11.08.021.001					700
A16.08.016					600
A16.25.007	(1)				500
A11.08.004					1300
A16.08.023	(1)				1800
A16.08.023	(2)				3000
					250
					350
A11.25.003.001					600
A16.01.017.001)		-	1	.(1	3300
A16.01.017.001)		-	1	3 .(1	3500
A16.25.008					1500
A16.08.011					1200
					500
	()				900
	()				1400
	()				1200
B01.003.004.004					300
					300
B01.003.004.005	(I)				500
B01.003.004.005	(II)				700
B01.003.004.005	(III)				900
	()				200
	()				200
	()				200
A11.08.020					200
	()				6000
A03.25.001					400
A16.08.012					800
					700
					300
A16.01.017.001)		-	1	.(1	3800
A16.01.017.001)		-	1	3 .(1	4000
					4000
A16.08.009.001		-1	:	1	10000
A16.08.009.001		-1	:	2	20000
A16.08.009.001		-1	:	3	30000
A16.08.010.001 ()			:	1	10000
A16.08.010.001 ()			:	2	15000
A16.08.010.001 ()			:	3	20000
A16.25.020					13000
A16.25.011 ()					1500
A16.25.011 ()					2000
B01.003.004.001 ()					1000

	:1		12000
	:2		15000
	:3		20000
			700
			1000
A16.08.013	()	: 1	18000
A16.08.013	()	: 2	24000
A16.08.013	()	: 3	29000
A16.08.001	()) 1	31000
			1000
A16.08.014		1	10000
A15.03.003			1500
	-		7000
A16.08.012			3500
A16.08.017.001		1	30000
A16.08.017.001		2	37000
A16.08.017.001		3	42000
A16.08.035			35000
A16.08.002		1	25000
A16.08.002		2	34500
A16.08.001		3	39000
A16.08.001	()) 2	34000
A16.08.001	()) 3	39000
			5000
A16.08.064		1	15000
A16.08.064		2	20000
A16.08.064		3	25000
A16.08.014		2	15000
A16.08.014		3	20000
			710
			2200
A04.12.014			900
	()		1300
A04.12.003.001 ()			900
A04.12.002.002			1100
A04.12.002.001			2000
A04.12.002			1800
A04.12.002.003			1000
A04.12.001			1000
A04.12.001.001			1100
A04.12.001.002			600

	()		1500
A04.22.001			500
			700
			800
A04.16.001	(, , , ,)		1100
	(,) , , ,		1800
A04.14.001			700
A04.14.002			500
A04.14.002.001			650
A04.06.001			500
A04.15.001			500
A04.18.001			500
A04.28.002.001			800
A04.22.002			400
A04.28.001			700
A04.28.002.001			600
A04.28.002.005			600
A04.28.002.003			500
A04.28.003			700
A04.10.002	(+)		1650
A04.01.001	()		750
A04.09.001			600
A04.06.003			600
A04.06.002			800
A04.06.002			800
A04.06.002			600
A04.06.002	/		600
A04.06.002			600
A04.06.002			600
A04.06.002	, / , , , ,		1900
A04.21.001			700
A04.20.001	()		850
A04.20.002	()		850
A04.20.002.001	()		950
A04.20.002	()		700

A04.23.001	()		900
(+)			
A04.23.001	() ()		700
A04.03.001	1		700
A04.07.002			600
A04.08.001	(4-5)		500
A04.04.001.001	(1)		600
A04.03.001			600
A04.04.001	(- / -)		450
B01.059.001	(,) -		1200
B01.059.002	(,) -		1100
A03.08.004.002			6900
A03.16.001	()		2300
A11.16.002	- ()		900
	IgA Helicobacter pylori)		850
A26.19.098	Helicobacter pylori ()		870
A11.16.002	/		1040
	Helicobacter pylori IgG (-)		3220
A11.16.002	()		400
A03.16.001.005	()		2900
			2000
A11.16.001	()		400
A11.16.003	()		400
A03.16.001.001			4900
A03.16.001.004			2400
A11.16.010			1100
A16.12.020.002			4900
A16.16.041.001			6500
A16.16.041.003			5000
A16.16.048			5000
A03.18.001.001			2600
A03.19.002			1800
A11.18.001	()		400
A11.19.001	()		400
A11.19.002	()		400
A16.18.019.001	(1)		6900
A16.18.019.001	(1 2-)		8100
A16.18.019.001	(2-)		10900
A03.18.002			11900
A03.19.004			3100

A03.09.001		2900
A03.08.001.001	()	2600
A11.07.016.001	()	400
A11.08.003.001	()	400
A11.08.008.001	()	400
A11.08.012.001	()	400
A03.09.002		2900
A03.09.003		3300
A03.16.002		500
A03.30.006.001		2900
A11.09.008		400

	()	1200
	()	1100

B01.027.001	(,) -	1200
B01.027.002	(,) -	1100

	(60)	2100
--	-------	------

Check-Up	45	11499
Check-Up	40	12799
Check-Up	45	15599
Check-Up	40	16999
Check-Up (-)"	" 40	7100
Check-Up (-)"	" 40	8800
")"	" (; ;	2990
")"	" (+	1999
")"	" (+	1600
" +	" (+ +	7500

B01.004.001	(,) -	1200
B01.004.002	(,) -	1100

A11.12.003.001	()	400
A11.12.003	()	250

A11.01.002				170
A11.02.002				200
A11.16.010				1100
A11.12.003.001 () 2 .				200
A11.12.003.001 () 8				100
A11.12.003.001 () 5				100
A11.12.003.001 () 30 /1 (1)				50
A11.12.003.001 () 5 / 100 (1)				450
A11.02.002 5 / (1)				50
A11.02.002 50 / (1)				50
A11.12.003.001 () 10				230
A11.12.003.001 () 5				300
A11.02.002 2 .				200
()				1200
()				1100
B01.008.001 (,) -				1200
B01.008.002 (,) -				1100
B01.023.003 3-)	-	(1200
B01.058.006 3-)	-	(1200
B01.047.009 3-)	-	(1200
B01.003.001 () - -				1200
B01.003.002 () - -				950
B01.003.004.009 ()				3200
B01.003.004.009				4200
B01.003.004.009 ()				5300
B01.003.004.009 30				5500
B01.003.004.009 1				10000
B01.003.004.012 30				6500
B01.003.004.012 1				12000
B01.003.004.009 1,5				15000
B01.003.004.007 1				9900

B01.003.004.007		2-		14000
B01.003.004.008	-		1	11900
B01.003.004.008	-		2-	16000
B01.003.004.007		30		5500

	/	(1 -)	()	5000
	-			5000
B01.003.003	-		-	5000
				3000

	(,)	-		1200
	(,)	-		1100

	(,1)			6500
	()1			3100
	()1			1500
	()2			2100
				15000
	1)		(2100
				5900
				15000
				1800
				1100
				600
				600
	/			700
				6100
				10000
	1			8600
	2			11600
	3			15100
			(1)	7000

	(,1)1			10100
	(,1)2			15100
	(/)1			11900
	(/)2			15900
)1		(6300
)2		(9300
	()1			19000
	()2			23000

()3	29000
()1	27000
()2	31900
()3	45100
1	20100
2	24100
3	37100

"A" "M", "A1" "B1"	1300
"A" "M", ()	1700
"B" "BE", "B1" ()	1300
"B" "BE", "B1" () (-)	1700

B01.050.001 (,) - -	1200
B01.050.002 (,) - -	1100

A11.04.003	1100
A11.04.004	1200
A15.02.001	500
A15.03.001	500
A15.03.003	700
A15.03.003.002	600
A15.03.007	600
A15.03.009	700
A15.03.010 ()	500
A15.03.010.001	600
A15.04.001 ()	700
A16.02.007 ()	29900
A16.02.008 ()	29900
A16.02.009	26000
A16.03.034	2600
A16.04.003	23000
A16.04.018	3100
A16.30.032	1300
A16.30.032	1500
A16.30.032	1900
A16.30.032	2400

	150
--	-----

I, II, III, IV. SMN1, . ((Spinal Muscular Atrophy, SMA, Type I, II, III, IV, Gene SMN1, Mut. (Only Presence One Gene Copy))	31140
CINCA, NLRP3 . (Chronic Infantile Neurologic Cutaneous Articular, Gene NLRP3, Mut.)	46680
TBX3, . (Pallister W Syndrome, Gene TBX3, Mut.)	27250
RABPN1, . . . (Oculopharyngeal Muscular Dystrophy, OPMD, Gene RABPN1, Freq. Mut.)	4680
PRNP, . . (Gerstmann-Straussler Disease, Gene PRNP, Mut.)	13560
((Bloch-Sulzberger Syndrome, Familial Incontinentia Pigmenti, Gene IKBKG, Freq. Mut.)	4680
GJB2	10240
NS3, NS5A NS5B (3)	11670
RAB27A, . (Griscelli Syndrome, Gene RAB27A, Mut.)	19480
C1NH, . (Hereditary Angioedema Type I, Gene C1NH, Mut.)	27250
(() I. 22, . (Charcot-Marie-Tooth Disease Type 1B, Gene 22, Mut.)	15930
HRAS, . (Costello Syndrome, Gene HRAS, Mut.)	6510
RMRP, . (Metaphyseal Chondrodysplasia, McKusick Type, Gene RMRP, Mut.)	6510
MEFV, . (Familial Mediterranean Fever, FMF, Gene MEFV, Mut.)	37750
SBDS1, . . . (Shwachman-Diamond Syndrome, Gene SBDS1, Freq. Mut.)	6510
HLA-A29	3000
ACVR1, « . » . . (Fibrodysplasia Ossificans Progressiva, FOP, Gene ACVR1, without Hot-Point Mut.)	27250
EDNRB, . (Waardenburg-Shah Syndrome, Gene EDNRB, Mut.)	27250
ERCC6, . (Cockayne Syndrome, Gene ERCC6, Mut.)	85530
SLC26A2, . (Diastrophic Dysplasia, Gene SLC26A2, Mut.)	23370
B1. ROR2, . (Brachydactyly Type B1, Gene ROR2, Mut.)	12970
(). GLI3, . (Greig Syndrome, Gene GLI3, Mut.)	69990
	8100
(() I. EGR2, . (Charcot-Marie-Tooth Disease Type 1B, Gene EGR2, Mut.)	15600
7 9 FGFR2, . (Crouzon Syndrome, Exons 7, 9 Gene FGFR2, Mut.)	9090
- a - a (). ENG, . (Rendu-Osler-Weber Disease, Gene ENG, Mut.)	35020
NDP, . (Familial Exudative Vitreoretinopathy, FEVR, Gene NDP, Mut.)	10240
LMNA, . (Familial Partial Lipodystrophy 2, Gene LMNA, Mut.)	38910
(). LMX1B, . (Nail-Patella Syndrome, NPS, Onychoosteodysplasia, Gene LMX1B, Mut.)	27250
SGCE, . (Myoclonic Dystonia, Gene SGCE, Mut.)	46680
ATP7B, . . (Wilson Disease, Gene ATP7B, Freq. Mut.)	9350
, NGF . (Hereditary Sensory and Autonomic olynuropathy, Gene NGF, Mut.)	15600
« » ALMS1, « . » . . (Alstrom syndrome, Gene ALMS1, Hot-Point Mut.)	12970
(()). TCOF1, . (Treacher-Collins Syndrome, Franceschetti-Klein Syndrome, Mandibulofacial Dysostosis without Limb Anomalies, Gene TCOF1, Mut.)	85530
GJB3, . (Erythrokeratoderma, Gene GJB3, Mut.)	10240

, GLA, .	9200
« » TRPV4, « » . . (Distal Spinal Muscular Atrophy Congenital Non-Progressive, Gene TRPV4, Hot-Point Mut.)	12970
Primary Carnitine Deficiency, SPCD, Carnitine Deficiency Systemic Primary, CDSP, Gene SLC22A5, Mut.)	38910
FXN, . . (Friedrich Ataxia, Gene FXN, Freq. Mut.)	8200
EMG1, . (Bowen Conradi Syndrome, BCS, Gene EMG1, Mut.)	15600
(Leber Hereditary Optic Neuropathy, LHON, Mitochondrial DNA, 3 Freq. Mut.)	4680
Syndrome, Gene BCS1L, Mut.)	15930
BCS1L, . (Bjomstad Syndrome, Gene BCS1L, Mut.)	13560
TWIST1, . (Saethre-Chotzen Syndrome, Gene TWIST1, Mut.)	23370
GDAP, . (Charcot-Marie-Tooth Disease Type 2A1, Gene GDAP, Mut.)	6200
COMP, . . (Pseudoachondroplasia, Gene COMP, Freq. Mut.)	69990
NPHS1, . (Nephrotic Syndrome Type 1, NPHS1, Gene NPHS1, Mut.)	10960
FGFR3, . . (Achondroplasia, Gene FGFR3, Freq. Mut.)	46680
NLRP3 . (Familial Cold Autoinflammatory Syndrome, FCAS, Gene NLRP3, Mut.)	15600
O, . (Charcot-Marie-Tooth Disease Type 1B, Gene O, Mut.)	27250
DLL3, . (Spondylocostal Dysostosis, Gene DLL3, Mut.)	15460
NPHP1, . (Nephronophthisis 1, NPHP1, Gene NPHP1, Mut.)	31140
FHL1, . (Emery-Dreifuss Muscular Dystrophy, Gene FHL1, Mut.)	46680
ANKH, . (Chondrocalcinosis, Calcium Pyrophosphate Dihydrate, CPPD, Gene ANKH, Mut.)	9090
MULIBRAY. TRIM37, . (Muscle-Liver-Brain-Eye, Gene TRIM37, Mut.)	12970
(Leber Hereditary Optic Neuropathy, LHON, Mitochondrial DNA, 12 Freq. Mut.)	4680
Ataxia, Gene ATXN7 Freq. Mut.)	58330
IGHMBP2, . (Distal Spinal Muscular Atrophy 1, DSMA1, Gene IGHMBP2, Mut.)	19480
RP2, Mut.)	9350
RP2, . (Retinitis Pigmentosa, Gene RP2, Mut.)	57020
Syndrome, Type VI, Gene PLOD, Freq. Mut.)	4680
(Aarskog-Scott Syndrome, Faciodigitogenital Syndrome, Faciogenital Dysplasia, Gene FGD1, Mut.)	10620
Spinal and Bulbar Muscular Atrophy, Gene AR, Freq. Mut.)	5790
AR, . . (Kennedy Syndrome, Gene AR, Freq. Mut.)	3100
PCSK9	69990
() X	6510
/ , FMR1, . .	12970
GLI3, . (Pallister-Hall Syndrome, Gene GLI3, Mut.)	10730
9 FGFR2, . (Antley-Bixler Syndrome, ABS, Exon 9 Gene FGFR2, Mut.)	4680
7, 9 FGFR2 7A FGFR1, . (Pfeiffer Syndrome, Exons 7, 9 Gene FGFR2, Exon 7A Gene FGFR1, Mut.)	31140
/	
UNC13D, . . (Familial Hemophagocytic Lymphohistiocytosis, Gene UNC13D, Freq. Mut.)	
TNFRSF6, . (Autoimmune Lymphoproliferative Syndrome, ALPS, Gene TNFRSF6, Mut.)	

(Familial Meddulary Thyroid Cancer, Exons 5, 8 Gene RET, Mut)	5, 8	RET, .	9090
Syndromе, Gene SBDS, Mut.)	SBDS, . (Shwachman-Diamond		19480
Mut)	KCNJ2, . (Andersen-Tawil Syndrome, Gene KCNJ2,		15930
ABCA4, . . (Stargardt Disease 1, STGD1, Fundus Flavimaculatus Included, Gene ABCA4, Freq. Mut)	(1-)		10960
	CHM, . (Choroideremia, CHM, Gene CHM, Mut.)		58330
			6900
WWS, Gene FKRP, Mut)	().	FKRP, . (Walker-Warburg Syndrome,	13560
Syndromе with Acanthosis Nigrіcan, CAN, Exon 10 Gene FGFR3, Mut)	10	FGFR3, . (Crouzon	6510
Agammaglobulinemia, XLA, Gene BTK, Mut.)	BTK, . (X-Linked		69990
	D- ().		85530
Progressive, Gene GRN, Mut.)	PHEX, . (Hypophosphatemic Vitamin D-Resistant Rickets, Gene PHEX, Mut.)	GRN, . (Aphasia Primary	23370
	XK, . (McLeod Syndrome, Gene XK, Mut.)		15600
(Testicular Feminization Syndrome, Gene AR, Mut)	(,)	AR, .	38910
Ectodermal Dysplasia, Gene EDA, Mut.)		EDA, . (Anhidrotic	31140
UPK3A, Mut.)	UPK3A, . (Renal Hypodysplasia, Aplasia 1, Gene		23370
Mut)	PAH, . . (Phenylketonuria, PKU, Gene PAH, Freq.		15460
« . » . . (Optic Atrophy With Or Without Deafness, Ophthalmoplegia, Myopathy, Ataxia And Neuropathy, Gene OPA1, Hot-Point Mut)	« »	OPA1,	9090
Dominant, SCN1, Gene ELA2, Mut.)	ELA2, . (Neutropenia Severe Congenital 1 Autosomal		19480
	APOB100		4380
(Congenital Insensitivity To Pain With Anhidrosis, CIPA, Gene NTRK1, Mut.)		NTRK1, .	46680
Epiphysial Dysplasia, MED, Gene COMP, Freq. Mut)		COMP, . . (Multiple	6200
PHOX2B, . . (Congenital Central Hypoventilation Syndrome, CCHS, Gene PHOX2B, Freq. Mut)	().		4680
(Genes CFTR, GJB2, PAH, SMN))	(CFTR, GJB2, PAH, SMN) (Main Hereditary Diseases		19220
Gene DMPK, Freq. Mut.)	DMPK, . . (Myotonic Dystrophy 1,		4680
	(- -) l.		9090
ongenital Ichthyosis, ARCI 1, All Known Mutations, Gene TGM1, Mut.)	TGM1, . (Autosomal Recessive		38910
Motor Neuropathy, DHMN, Gene BSCL2, Mut.)	v.	BSCL2, . (Distal Hereditary	27250
Mut)	ZEB2, . (Mowat-Wilson Syndrome, Gene ZEB2,		58330
(Phosphoribosylpyrophosphate Synthetase Superactivity, PRS Superactivity, Gene PRPS1, Mut.)		PRPS1, .	27250
(Albinism culocutaneous, Hermansky-Pudlak ype, Gene HPS1, Freq. Mut.)	().	HPS1, . . .	9090
	/		21400
(Klippel-Feil Syndrome, Gene GDF6, Mut)	().	GDF6, .	13560
. (Craniometaphyseal Dysplasia, Gene ANKH, Hot-Point Mut.)	« »	ANKH, « . » .	9090
(Nonbullous Congenital Ichthyosiform Erythroderma, NBCIE, Gene TGM1, Mut.)	().	TGM1, .	38910

PRNP, Mut.)	PRNP, . (Creutzfeldt-Jakob Disease, Gene	13560
Gene CRYBA4, Mut.)	CRYBA4, . (Microphthalmia with Cataract,	23370
	:	6900
(TNF-Receptor-Associated Periodic Syndrome, TRAPS, Gene TNFRSF1A, Mut.)	TNFRSF1A, .	23370
Cerebelloparenchymal Disorder IV, CPD IV, Classic Joubert Syndrome, Joubert Syndrome type A, Joubert-Boltshauser Syndrome, Pure Joubert Syndrome, Gene NPHP1, Mut.)	NPHP1 (Joubert Syndrome,	15460
, CYB5R3 . . (Methemoglobinemia, Gene CYB5R3, Freq. Mut.)		4680
Mut.)	IT15, . . (Chorea Huntington, Gene IT15, Freq.	4680
Syndrome, Type 1, SGBS1, Gene GPC3, Mut.)	GPC3, . (Simpson-Golabi-Behmel	31140
III, Gene OPA3, Mut.)	OPA3, . (3-Methylglutaconic Aciduria Type	10240
-	(), XIAP	31140
. (X-Linked Lymphoproliferative Syndrome, XLP, Gene XIAP, Mut.)		
FMF, Gene MEFV, Freq. Mut.)	MEFV, . . (Familial Mediterranean Fever,	9070
Gene SRY, Mut.)	SRY, . (Disorders Sex Determination,	6510
Dysplasia, Gene GJB6, Mut.)	GJB6, . (Hidrotic Ectodermal	10240
-	FRMD7, . (X-Linked Nystagmus	46680
congenital 1, NYS1 X-Linked, Gene FRMD7, Mut.)		
Mut.)	ALX4, . (Parietal Foramina, PFM, Gene ALX4,	15600
WAS, Gene WAS, Mut.)	(). WAS, . (Wiskott-Aldrich Syndrome,	27250
	, . (Emery-Dreifuss Muscular Dystrophy, X-Linked Gene Emerine, Mut.)	13560
Enteropathica, Gene SLC39A4, Mut.)	SLC39A4, . (Acrodermatitis	31140
	22, . (Hereditary Neuropathy with Liability to Pressure Palsies, HNPP, Gene 22, Mut.)	15930
	(). TCIRG1,	4680
. . (Osteopetrosis Autosomal Recessive 1, OPTB1, Gene TCIRG1, Freq. Mut.)		
SCN4A, . (Hypokalemic Periodic Paralysis Type 1, Exons 12, 18, 19 Gene SCN4A, Mut.)	12, 18 19	12970
Mut.)	FLG, . (Ichthyosis Vulgaris, Gene FLG, Freq.	9090
	, LDLR	11670
-IgD Mut.)	CD40LG, . (Hyper-IgD Syndrome, Gene CD40LG,	38910
IA, Gene TYR, Mut.)	1 . TYR, . (Albinism Oculocutaneous Type	19480
Dystrophy-Dystroglycanopathy, Gene FKR1, Freq. Mut.)	FKR1, . . (Muscular	7160
Fundus Flavimaculatus Included, Gene ABCA4, Freq. Mut.)	ABCA4, . . (Stargardt Disease 1, STGD1,	10960
(Spondyloepiphyseal Dysplasia Tarda, SEDT, Gene TRAPPC2, Mut.)	(). TRAPPC2, .	15600
Pneumothorax, PSP, Gene FLCN, Mut.)	FLCN, . (Primary Spontaneous	46680
	, NBN . . (Nijmegen Breakage Syndrome, NBS, Gene NBN, Freq. Mut.)	4680
PAX3, Mut.)	PAX3, . (Waardenburg Syndrome, WS, Gene	31140
Dystrophy Limb-Girdle Type 2A, Gene FKR1, Mut.)	FKR1, . (Muscular	13560
	CTSK, . (Pyknodysostosis, PKND, Gene CTSK, Mut.)	23370
	PAH, . (Phenylketonuria, PKU, Gene PAH, Mut.)	46680
Syndrome, Gene DHCR7, Mut.)	(). DHCR7, . (Smith-Lemli-Opitz	35020
	CFTR, . . (Cystic Fibrosis, Gene CFTR, Freq. Mut.)	15460

	8000
NOTCH3	11200
Muscular Dystrophy, X-Lyonization, Girls) (Duchenne	7300
GDF6, Mut.) GDF6, . (Microphthalmia Isolated 4, Gene	13560
	6900
SPM, Gene FHL1, Mut.) FHL1, . (Scapulooperoneal Myopathy,	31140
Hemophagocytic Lymphohistiocytosis, Gene PRF1, Mut.) PRF1, . (Familial	19480
Gene PRNP, Mut.) PRNP, . (Fatal Familial Insomnia, FFI,	13560
	46680
Myoclonic Epilepsy 1A Unverricht and Lundborg, Gene CSTB, Freq. Mut.) EXT1, . (Multiple Exostoses, Gene EXT1, Mut.)	4680
ACVR1, « » . . (Fibrodysplasia Ossificans Progressiva, FOP, Gene ACVR1, Hot-Point Mut.)	15600
	3100
(X-Linked Severe Combined Immunodeficiency, Gene IL2RG, Mut.) 2, JPH3, . .	15600
	46690
Elasticum, Gene ABCC6, Freq. Mut.) NLRP3 . (Muckle-Wells Syndrome, MWS, Gene NLRP3, Mut.)	6510
	31140
Hypertension 1, PPH1, Gene BMPR2, Mut.) ABCC6, . . (Pseudoxanthoma	58330
	19480
	10240
(Nonbullous Congenital Ichthyosiform Erythroderma, NBCIE, Gene LOX12B, Mut.)	38910
Cardiomyopathy, Gene TNNT2, Mut.) TNNT2, . (Familial Hypertrophic	46680
(Primary Open Angle Glaucoma 1A, POAG 1A, Gene CYP1B1, Mut.)	15930
	101070
Thrombocytopenia, CAMT, Gene MPL, Mut.) FLT4, . (Lymphedema, Gene FLT4, Mut.)	31140
Dystrophy Limb-Girdle Type 2A, Gene SGCB, Mut.) MPL, . (Congenital Amegakaryocytic	23370
Hypodysplasia, Aplasia 1, Exons 10, 11, 13, 14, 15 Gene RET, Mut.)	19480
Heteroplasia, POH, Gene GNAS, Mut.)	35020
	6700
	3100
Syndrome, PPS, Gene IRF6, Mut.)	35020
PTEN, Mut.)	35020
Dystrophy-Dystroglycanopathy, Gene FKRP, Mut.)	13560
Syndrome, Gene PTEN, Mut.)	35020
VHL, . (Autosomal Recessive Erythrocytosis, Gene VHL, Mut.)	13560
disease type 1A (CMT1A))	15070
Gene ANKH, Mut.)	46680
Disease, CGD, Gene CYBB, Mut.)	46680

LMNA, . (Hutchinson-Gilford Progeria Syndrome, Gene LMNA, Mut.)	38910
UGT1, . (Crigler-Najjer Syndrome, Gene UGT1, Mut.)	19480
MECP2, . (Retts Syndrome, Gene MECP2, Mut.)	19480
HLA B51	3000
SRY, . (Disorders Sex Determination, Analysis Gene SRY, Mut.)	4680
SGCA, . (Muscular Dystrophy Limb-Girdle Type 2A, Gene SGCA, Mut.)	23370
NEFL, . (Charcot-Marie-Tooth Disease Type 2A1, Gene NEFL, Mut.)	23370
TNFRSF6, « . » . . (Autoimmune Lymphoproliferative Syndrome, ALPS, Gene TNFRSF6, Hot-Point Mut.)	6510
-IgD « . » MVK, « . » . . (Hyper-IgD Syndrome, Gene MVK, Hot-Point Mut.)	9090
FKTN, . (Muscular Dystrophy Fukuyama-Type, Gene FKTN, Mut.)	46680
ESC (.) . NR2E3, . (Enhanced S- one Syndrome, Goldmann-Favre Syndrome, Gene NR2E3, Mut.)	23370
IRF6, . (Van der Woude Syndrome, Gene IRF6, Mut.)	35020
RS1, . (Retinoschisis 1 X-Linked Juvenile, RS1, Gene RS1, Mut.)	23370
UNC13D, . (Familial Hemophagocytic Lymphohistiocytosis, Gene UNC13D, Mut.)	69990
(.) . TCIRG1, . (Osteopetrosis Autosomal Recessive 1, OPTB1, Gene TCIRG1, Mut.)	46680
CSTB, . (Progressive Myoclonic Epilepsy 1A Unverricht and Lundborg, Gene CSTB, Mut.)	12970
(.) . SH2D1A, . (X-Linked Lymphoproliferative Syndrome, XLP, Gene SH2D1A, Mut.)	15600
BEST1, . (Best Vitelliform Macular Dystrophy, All Known Mutations, Gene BEST1, Mut.)	38910
TWIST1, . (Craniosynostosis Type 2, Gene TWIST1, Mut.)	13560
MSX2, . (Craniosynostosis Type 2, Gene MSX2, Mut.)	10240
PRNP, . (Spongiform Encephalopathy with Neuropsychiatric Features, Gene PRNP, Mut.)	13560
KRT2, . (Ichthyosis Bullosa Of Siemens, Gene KRT2, Mut.)	27250
(.) . RAB23, . (Carpenter Syndrome, Gene RAB23, Mut.)	27250
9 FGFR2 7A FGFR1, . (Jackson-Weiss Syndrome, JWS, Exon 9 Gene FGFR2, Exon 7A Gene FGFR1, Mut.)	9090
ABCC6, . (Pseudoxanthoma Elasticum, Gene ABCC6, Mut.)	108840
, 4, SPAST (SPG4), . .	6300
(.) . VHL, . (Von Hippel-Lindau Syndrome, VHL, Von Hippel-Lindau Hereditary Cancer Syndrome, Gene VHL, Mut.)	13560
HLA-Cw6	3000
(.) . FGFR2, . . (Apert Syndrome, AS, Gene FGFR2, Freq. Mut.)	5090
(.) . LDLR, APOB, PCSK9)	9350
SLC26A2, . (Multiple Epiphysial Dysplasia, MED, Gene SLC26A2, Mut.)	8380
PRPS1, . (Art's Syndrome, Gene PRPS1, Mut.)	23370
(.) . ALOXE3, . (Nonbullous Congenital Ichthyosiform Erythroderma, NBCIE, Gene ALOXE3, Mut.)	27250
PAX3, . (Craniofacial-Deafness-Hand Syndrome, CDHS, Gene PAX3, Mut.)	58330
	31140

Muscular Dystrophy, Gene LMNA, Mut.)	LMNA, . (Emery-Dreifuss	38910
VHL, . . (Autosomal Recessive Erythrocytosis, Gene VHL, Freq. Mut.)	(C .).	4680
(Keratitis-Ichthyosis-Deafness Syndrome, KID Syndrome, Gene GJB2, Mut.)	GJB2, .	9090
« . » . . (Familial Partial Lipodystrophy 2, FPLD 2, Gene LMNA, Hot-Point Mut.)	« . » . . LMNA,	12970
TAZ, . (Barth Syndrome, Gene TAZ, Mut.)	TAZ, . (Barth Syndrome, Gene TAZ, Mut.)	23370
(Cerebrooculofacioskeletal Syndrome, COFS Syndrome, Gene ERCC6, Mut.)	ERCC6, .	85530
VHL, . (Von Hippel-Lindau Syndrome, VHL, Von Hippel-Lindau Hereditary Cancer Syndrome, Gene VHL, Copy Number Variation Gene VHL, Mut.)	(. .).	15070
EXT2, . (Multiple Exostoses, Gene EXT2, Mut.)	EXT2, . (Multiple Exostoses, Gene EXT2, Mut.)	58330
ANO5, SGCA	CAPN3, FKRP,	10960
3A, Gene CYP1B1, Mut.)	CYP1B1, . (Primary Congenital Glaucoma 3A, PCG	15930
(Normokalemic Periodic Paralysis, Exon 13 Gene SCN4A, Mut.)	13 SCN4A, .	6510
ATP7B, PNPLA3, SERPINA1, . .	ATP7B, PNPLA3, SERPINA1, . .	8400
GLI3, . (Polydactyly, Gene GLI3, Mut.)	GLI3, . (Polydactyly, Gene GLI3, Mut.)	69990
-IgM Mut.)	CD40LG, . (Hyper-IgM Syndrome, Gene CD40LG,	19480
HPGD, . (Hypertrophic Osteoarthropathy, Primary, Autosomal Recessive, 1, Gene HPGD, Mut.)	(.).	27250
Gene CLCN1, Freq. Mut.)	CLCN1, . . (Myotonia Congenita,	9350
, C9orf72, . .	, C9orf72, . .	4200
And Diabetes Syndrome, Gene HNF1B, Mut.)	HNF1B, . (Renal Cysts	35020
SH3TC2, FIG4, FGD4 GDAP1, . . (Charcot-Marie-Tooth Disease Type 1B, Gene GDAP1, Freq. Mut.)	(. .) I.	9350
Gene RPS6KA3, Mut.)	(.). RPS6KA3, . (Coffin-Lowry Syndrome,	85530
SHH, . (Polydactyly, Gene SHH, Mut.)	SHH, . (Polydactyly, Gene SHH, Mut.)	9090
, . PNPLA3, . .	, . PNPLA3, . .	2900
TAR. RBM8A, . (Thrombocytopenia-Absent Radius Syndrome, TAR-Syndrome, Gene RBM8A, Mut.)	TAR. RBM8A, . (Thrombocytopenia-Absent Radius Syndrome,	23370
PTEN, . (Cowden Syndrome 1, Gene PTEN, Mut.)	PTEN, . (Cowden Syndrome 1, Gene PTEN, Mut.)	35020
, 2, CNBP (ZNF9), . .	, 2, CNBP (ZNF9), . .	2800
(Chondrodysplasia Punctata, CDP, Conradi-Hunermann Syndrome, Gene EBP, Mut.)	EBP, .	15600
Hemophagocytic Lymphohistiocytosis, Gene STXBP2, Mut.)	STXBP2, . (Familial	46680
(.).	(.). LPIN1, . (Myoglobinuria Acute Recurrent	85530
Autosomal Recessive, Gene LPIN1, Mut.)	Autosomal Recessive, Gene LPIN1, Mut.)	
Gene ADAMTSL2, Mut.)	ADAMTSL2, . (Geleophysic Dysplasia 1,	69990
(Neurodegeneration With Brain Iron Accumulation 1, Gene PANK2, Freq. Mut.)	PANK2, . .	6510
GJB4, . (Erythrokeratoderma, Gene GJB4, Mut.)	GJB4, . (Erythrokeratoderma, Gene GJB4, Mut.)	9090
(.).	(.). SLC26A2, . (Atelosteogenesis	23370
II, De la Chapelle Dysplasia, Gene SLC26A2, Mut.)	II, De la Chapelle Dysplasia, Gene SLC26A2, Mut.)	
DBA1, Gene RPS19, Mut.)	RPS19, . (Diamond-Blackfan Anemia 1,	19480
NPHS1, Gene NPHS2, Mut.)	NPHS2, . (Nephrotic Syndrome Type 1,	31140
IX, Mut.)	IX B, . (Hemophilia B, Gene Factor	27250
Syndrome, TRPS, Gene TRPS1, Mut.)	TRPS1, . (Trichorhinophalangeal	38910

Muscular Atrophy (SMA) with Diaphragmatic Paralysis, Gene IGHMBP2, Mut.)	IGHMBP2, . (Spinal	58330
Freq. Mut.)	FGFR3, . . (Hypochondroplasia, Gene FGFR3,	10960
(1 , 1b)	NS3, NS5A NS5B	11670
. (Hyperkalemic Periodic Paralysis Type 2, Exons 13, 24 Gene SCN4A, Mut.)	13 24 SCN4A,	14270
DFNB1	GJB2	6200
MET		11210
(Hereditary Breast and/or Ovarian Cancer, HBOC (Genes BRCA1, BRCA2))	/ (BRCA1, BRCA2)	4350
POLE		7570
1 /19q		10150
		9100
Neoplasia Type 2B (Gene RET)	2B (RET) (Multiple Endocrine	4680
BRCA-	(BRCA1, BRCA2) (3900
(Hereditary Breast Cancer In Men: Cancer of Breast, Pancreatic, Prostate, Testicular Cancer (Genes BRCA1, BRCA2) (without Description))		
Medullary Thyroid Cancer (Exons 10, 11, 13, 14, 15 Gene RET)	(10, 11, 13, 14, 15 RET) (Familial	19460
Endocrine Neoplasia Type 2A (Exons 10, 11 Gene RET)	2A (10, 11 RET) (Multiple	9090
IDH2		10620
		21090
14 JAK2 (Quantification of wild-type and mutant allelic ratio of gene JAK2 617V/617F)	617V/617F	8000
BRCA-	(BRCA1, BRCA2) (Hereditary Breast	4350
Cancer In Men: Cancer of Breast, Pancreatic, Prostate, Testicular Cancer (Genes BRCA1, BRCA2))		
MGMT		10620
PIK3CA		10620
228 250 TERT		7570
(Hereditary Breast and/or Ovarian Cancer, HBOC (Genes BRCA1, BRCA2) (without Description))	/ (BRCA1, BRCA2) (3900
IDH1		10620
(, L- , +) (Lactate Dehydrogenase, LDH)		150
G6PD		2980
(Alanine Aminotransferase, ALT, Serum Glutamic Pyruvic Transaminase, SGPT)	(, , - ,)	150
- (?- ,) (lpha- milase, ?-Amylase)		210
- (P-) (Pancreatic ?-Amylase)		250
(S- , S-)	II, S- ,)	230
(Cholinesterase, Pseudocholinesterase, PCHE)		
() (Alkaline Phosphatase, ALP)		150
() (Lipase)		290
() (Acid Phosphatase, ACP)		200
- (,) (Gamma-Glutamyl Transferase, GGT)		150
CPK)	(, ,) (Creatine Kinase, CK, Creatine Phosphokinase,	240
(Aspartateaminotransferase, AST, Serum Glutamicoxaloacetic Transaminase, SGOT)	(, , - ,)	150

	(Creatine Kinase-MB, CK-MB, Creatine Phosphokinase-MB, CPK-MB.)	310
HLA-		
	HLA II (DRB1, DQA1, DQB1) (System Human Leukocyte Antigen (HLA) Class II, Typing (Genes DRB1, DQA1, DQB1))	5310
	(Genotype of RH factor Definition (without Description))	8880
	Y- (Y-chromosome of the fetus in the mother's blood)	4100
	(Rh factor Definition)	6200
	(Plasminogen)	600
	VIII () (Antihemophilic Globulin A, FVIII)	1030
D-	(D-Dimer)	1030
	(Fibrinogen, FG)	210
	() () (Activated Partial Thromboplastin Time, APTT)	150
	IX, % (« » Factor IX, Activity,% (Christmas Factor, anti-hemophilic globulin "B"))	440
	() (Prothrombin, rothrombin Time, PT, International Normalized Ratio, INR)	230
	() (Thrombin Time, TT)	230
	() (Lupus Anticoagulant, LA)	730
	C, % (Protein C, % Activity)	1790
	/ (), Anti-Xa activity, IU/ml (Heparin concentration, IU/ml)	1670
	, % (Willebrand Factor, Antigen, %)	2030
	III, % (III, Antithrombin III, % Activity)	330
	S (Protein S, Free)	2220
	(Urine immunoglobulin free light chains (FLC) kappa and lambda)	1340
	(M-Gradient, Screening. Serum Protein Electrophoresis (SPEP), Immunofixation with Polyvalent Antiserum, Quantification of M-Protein (without Typing))	2160
	(Bence-Jones Protein, Urine, Electrophoresis, Immunofixation, Kappa/Lambda Typing, Quantification)	3000
	(Serum Protein Electrophoresis, SPE, SPE)*	250
	(M-Gradient, Typing. Serum Protein Electrophoresis (SPEP), Immunofixation with Antisera (IgG, IgA, IgM, Kappa, Lambda), Quantification of M-Protein)	3990
	(Cerebrospinal Fluid Concentration of Immunoglobulin Free Light Chains)	1580
	/	1960
	(Bence-Jones Protein, Urine, Immunofixation, Quantification)	1880
	(Albumin)	210
	(Protein Total)	150
	(Homocysteine)	1290
	(Urine Protein Electrophoresis)	1500
ImmunoCAP		
	(f216) IgE, ImmunoCAP	630
	(f33) IgE, ImmunoCAP	630
	, nArtv1 (w231) IgE, ImmunoCAP	1830

(f9) IgE, ImmunoCAP	630
(f260), IgE, ImmunoCAP (Broccoli, Brassica oleracea (f260), IgE, ImmunoCAP)	720
(f26) IgE, ImmunoCAP	630
() (i6) IgE, ImmunoCAP	630
(f343), IgE, ImmunoCAP (Raspberry, Rubus idaeus, IgE, ImmunoCAP)	720
(f35) IgE, ImmunoCAP	630
, nGal d3 (f323) IgE, ImmunoCAP	830
(Hollister-Stier) (hx2) IgE, ImmunoCAP	1250
Candida albicans (m5) IgE, ImmunoCAP	630
(i1) IgE, ImmunoCAP	630
(i3) IgE, ImmunoCAP	630
(c8) IgE, ImmunoCAP	630
(f95) IgE, ImmunoCAP	630
(f6) IgE, ImmunoCAP	720
(Saccharomyces cerevisiae) (f45) IgE, ImmunoCAP	630
, nGal d1 (f233) IgE, ImmunoCAP	830
, rAra h 2 (f423) IgE, ImmunoCAP	1830
, (e81) IgE, ImmunoCAP	630
/ D. pter nyssinus (d1) IgE, ImmunoCAP	630
, rBet v1/PR-10 (t215) IgE, ImmunoCAP	1830
(f23) IgE, ImmunoCAP	630
, nGal d2 (f232) IgE, ImmunoCAP	830
- , (nBos d5) (f77) IgE, ImmunoCAP	830
- (nBos d4) (f76) IgE, ImmunoCAP	830
(f92) IgE, ImmunoCAP	630
(f91) IgE, ImmunoCAP	630
, (e6) IgE, ImmunoCAP	630
, ImmunoCAP	2750
, rGly m 4/PR-10 (f353) IgE, ImmunoCAP	1830
, (e213) IgE, ImmunoCAP	630
(f75) IgE, ImmunoCAP	630
, (e1) IgE, ImmunoCAP	630
, rAra h 1 (f422) IgE, ImmunoCAP	1830
(Hollister -Stier) (h2) IgE, ImmunoCAP	630
c, rAra h 9 LTP (f427) IgE, ImmunoCAP	1830
, rCan f 1 (e101) IgE, ImmunoCAP	1830
(f83) IgE, ImmunoCAP	630
(w5) IgE, ImmunoCAP	630
Malassezia spp. (m227) IgE, ImmunoCAP	630
, rCan f 2 (e102) IgE, ImmunoCAP	1830
/ (k80) IgE, ImmunoCAP	630
(f31) IgE, ImmunoCAP	630
(f14) IgE, ImmunoCAP	630
(Greer Labs.) (h1) IgE, ImmunoCAP	630
c (k82) IgE, ImmunoCAP	630
Cladosporium herbarum (m2) IgE, ImmunoCAP	630

(w8) IgE, ImmunoCAP	720
(mx2) IgE, ImmunoCAP	1250
(f24) IgE, ImmunoCAP	630
, rPen a1 (f351) IgE, ImmunoCAP	1830
(f209) IgE, ImmunoCAP	630
(i71) IgE, ImmunoCAP	630
(f2) IgE, ImmunoCAP	630
() (f55) IgE, ImmunoCAP	630
(f210) IgE, ImmunoCAP	630
(f13) IgE, ImmunoCAP	630
, nArtv3 (w233) IgE, ImmunoCAP	1830
-5, rTri a 19 (f416) IgE, ImmunoCAP	1830
(fx15) IgE, ImmunoCAP	1250
, (e5) IgE, ImmunoCAP	630
(fx73) IgE, ImmunoCAP	1250
(fx5) IgE, ImmunoCAP	1250
(w204) IgE, ImmunoCAP	720
(f49) IgE, ImmunoCAP	630
Penicillium notatum (P.chrysogenum) (m1) IgE, ImmunoCAP	630
(f25) IgE, ImmunoCAP	630
, rCyp c 1 (f355) IgE, ImmunoCAP	1830
(i75) IgE, ImmunoCAP	630
(gx1) IgE, ImmunoCAP	1250
, rBet v2, rBet v4 (t221) IgE, ImmunoCAP	1830
(f11), IgE, ImmunoCAP	630
(m80) IgE, ImmunoCAP	630
Phadiatop ImmunoCAP, IgE	1570
, rPhl p1, rPhl p5 (g213) IgE, ImmunoCAP	1830
(f302) IgE, ImmunoCAP	720
, (nBos d8) (f78) IgE, ImmunoCAP	830
(mx1) IgE, ImmunoCAP	1250
V (c2) IgE, ImmunoCAP	630
(f227) IgE, ImmunoCAP	720
(tx9) IgE, ImmunoCAP	1250
(f12), IgE, ImmunoCAP (Pea, Pisum sativum, IgE, ImmunoCAP)	720
(f20) IgE, ImmunoCAP	720
() (f212), IgE, ImmunoCAP (Mushrooms, Agaricus hortensis, IgE, ImmunoCAP)	720
/ D. farina (d2) IgE, ImmunoCAP	630
(f88) IgE, ImmunoCAP	630
(f94), IgE, ImmunoCAP (Pear, Pyrus communis, IgE, ImmunoCAP)	720
(f17) IgE, ImmunoCAP	630
(f4) IgE, ImmunoCAP	630
(f208) IgE, ImmunoCAP	630
, nBos d6 BSA (e204) IgE, ImmunoCAP	1830
(f262), IgE, ImmunoCAP (Eggplant, Solanum melongena, IgE, ImmunoCAP)	720
(f221), IgE, ImmunoCAP (Coffee, Coffea spp., IgE, ImmunoCAP)	720

(f222) IgE, ImmunoCAP	720
(wx1) IgE, ImmunoCAP	1250
(f322) IgE, ImmunoCAP	720
(f93) IgE, ImmunoCAP	630
, rPhl p7, rPhl p12 (g214) IgE, ImmunoCAP	1830
, rFel d1 (e94) IgE, ImmunoCAP	1830
(f27) IgE, ImmunoCAP	630
(f84) IgE, ImmunoCAP	630
, nGal d4 (k208) IgE, ImmunoCAP	830
, nAmb a1 (w230) IgE, ImmunoCAP	1830
(w6) IgE, ImmunoCAP	630
(f48), IgE, ImmunoCAP (Onion, Allium cepa, IgE, ImmunoCAP)	720
G (c1) IgE, ImmunoCAP	630
(g6) IgE, ImmunoCAP	630
(t3) IgE, ImmunoCAP	630
, rFel d2 (e220) IgE, ImmunoCAP	1830
B (m81) IgE, ImmunoCAP	630
(f237), IgE, ImmunoCAP (Apricot, Prunus armeniaca, IgE, ImmunoCAP)	720
(f242), IgE, ImmunoCAP (Cherry, Prunus avium, IgE, ImmunoCAP)	720
Ig E ImmunoCAP	690
TSST (m226) IgE, ImmunoCAP	630
Alternaria alternata (m6) IgE, ImmunoCAP	630
Aspergillus fumigatus (m3) IgE, ImmunoCAP	630
(f47) IgE, ImmunoCAP	720
Phadiatop Infant ImmunoCAP, IgE	1990
, rAra h 3 (f424) IgE, ImmunoCAP	1830
(f1) IgE, ImmunoCAP	630
c (f7) IgE, ImmunoCAP	630
c, rAra h 8/PR-10 (f352) IgE, ImmunoCAP	1830
(f85) IgE, ImmunoCAP	630
, (f44) IgE, ImmunoCAP	630
(f225) IgE, ImmunoCAP	630
(i2) IgE, ImmunoCAP	630
(f300) IgE, ImmunoCAP	720
(f3) IgE, ImmunoCAP	630
, (e85) IgE, ImmunoCAP	630
, nCan f3 (e221) IgE, ImmunoCAP	1830
(w206) IgE, ImmunoCAP	720
Alternaria alternata, rAlt a 1 (m229) IgE, ImmunoCAP	1830
- HLA-B27 (Molecular Genetic Testing HLA-B27)	1550
() (Anti- ydic Citrullinated Peptide, anti-CCP)	1320
IgG () (Anti- eratin ntibodies, AKA, Anti-Filaggrin ntibodies, AFA, IgG)	2040
, IgA (IgA; Rheumatoid Factor, RF, IgA)	1120
() (Synovial Fluid Smear, Crystals)	1550

IgG (Anti-Mutated Citrullinated Vimentin Antibodies, Anti-MCV, Anti-Modified Citrullinated Vimentin Antibodies, Anti-Sa Antibodies, IgG)	(-M)	1380
(,)		
DNA, Scrape of Nasal Epithelial Cells)*	(CMV	250
Scrape of Faucial Epithelial Cells)*	(CMV DNA,	250
	(CMV DNA, Blood)*	380
	(CMV DNA, Exudate)*	250
	(CMV DNA, Serum)*	380
A IgM (Anti-CMV IgM)		490
Semen)*	(CMV DNA, Prostatic Fluid,	250
of Skin Epithelial Cells)*	(CMV DNA, Scrape	250
	(CMV DNA, Urine)*	250
(CMV DNA, Scrape of Urogenital Epithelial Cells)*		250
	(CMV DNA, Saliva)*	250
	(Cytomegalovirus, DNA)	370
Anti-CMV IgG		1040
A IgG (Anti-CMV IgG)		360
DNA, Scrape of Conjunctiva Epithelial Cells)*	(CMV	250
Fluid)*	(CMV DNA, Cerebrospinal	250
(Copper, random urine; Cu)		
(Cd) (Cadmium (Cd), Urine)		1180
(Co) (Cobalt (Co), Urine)		1180
(Tl) (Thallium (Tl), Urine)		1180
(I) (Iodine (I), Urine)		1180
(Mn) (Manganese (Mn), Urine)		1180
(Fe) (Iron (Fe), Urine)		1180
(Hg) (Mercury (Hg), Urine)		1180
(Al) (Aluminum (Al), Urine)		1180
()		680
(Zn) (Zinc (Zn), Urine)		1180
(Cu) (Copper (Cu), 24-Hours Urine)		1180
(Ni) (Nickel (Ni), Urine)		1180
(Se) (Selenium (Se), Urine)		1180
()		680
(Pb) (Lead (Pb), Urine)		1180
(As) (Arsenic (As), Urine)		1180
(Anti-Tetanus toxoid IgG)		
IgG (Anti-Tetanus toxoid IgG)		900
(,)		
(Ni) (Nickel (Ni), Serum)		250
(Hg) (Mercury (Hg), Food)		1180
()		680

(As)	(Arsenic (As), Serum)	250
(Cd)	(Cadmium (Cd), Serum)	250
(Co)	(Cobalt (Co), Serum)	250
(Ni)	(Nickel (Ni), lood)	1180
(Zn)	(Zinc (Zn), lood)	1180
	(Iodine, serum)	250
(Au)	(Gold (Au), Serum)	250
(Cu)	(Copper (Cu), Serum)	250
	()	680
(Cu)	(Copper (Cu), lood)	1180
(Pb)	(Lead (Pb), lood)	1180
(Mn)	(Manganese (Mn), lood)	1180
(Zn)	(Zinc (Zn), Serum)	250
(Li)	(Lithium (Li), serum)	250
(Cd)	(Cadmium (Cd), lood)	1180
(Se)	(Selenium (Se), Serum)	250
(Se)	(Selenium (Se), lood)	1180
(Mn)	(Manganese (Mn), Serum)	250
(Co)	(Cobalt (Co), lood)	1180
	(3 , Reverse Triiodthyronine).	5970
(Tl)	(Thallium (Tl), Serum)	250
	(())	680
(Mo)	(Molybdenum (Mo), Serum)	250

ATM (FISH,) (Analysis of ATM gene rearrangements (FISH, quantitative))		9850
MPL, (Analysis of MPL gene mutations, PCR, qualitative)		4390
BCL- 6 (der(3)(q27)) (FISH,) (Analysis of BCL- 6 gene rearrangements (der(3)(q27)) on paraffin slides (FISH Histology, quantitative))		13570
MLL/AF4 -t(4;11) (,) (Analysis of chimeric gene MLL/AF4 -t(4;11) (PCR, qualitative))		2260
BCL- 6 (der(3)(q27)) (FISH,) (Analysis of BCL- 6 gene rearrangements (der(3)(q27) (FISH, quantitative))		9850
13 - (del(13), -13) (FISH,) (Analysis of chromosome 13 monosomy, deletion - (del(13), -13) (FISH, quantitative))		9850
53 (FISH,) (Analysis of 53 gene deletion (FISH, quantitative))		9850
t(2;5)(p23;q35) (FISH,) (Analysis of translocation t(2;5)(p23;q35) on paraffin slides (FISH Histology, quantitative))		13570
(FISH,) (Analysis of all specific aberrations on paraffin slides (FISH Histology, quantitative))		13570
t(11;14)(q13;q32) (FISH,) (Analysis of translocation t(11;14)(q13;q32) on paraffin slides (FISH Histology, quantitative))		13570
t(11;14)(q13;q32) (FISH,) (Analysis of translocation t(11;14)(q13;q32) (FISH, quantitative))		9850
PML/RAR? -t(15;17) (,) (Analysis of chimeric gene PML/RAR? -t(15;17) (PCR, qualitative))		2260
CBF?/MYH1- inv(16),t(16;16) (,) (Analysis of chimeric gene CBF?/MYH1- inv(16),t(16;16) (PCR, qualitative))		2260
12 (+12) (FISH,) (Analysis of chromosome 12 trisomy (FISH, quantitative))		9850
V617F 14 JAK2 (Qualitative assessment of presence of gene JAK2 617F somatic mutation)		1770
t(11;18)(q21;q21) (FISH,) (Analysis of translocation t(11;18)(q21;q21) (FISH, quantitative))		9850

(Karyotype, Hematologic Disorders, Peripheral Blood)	7020
53 (FISH, .) (Analysis of 53 gene deletion (FISH, quantitative))	9850
t(14;16) (IGH/MAFB) (FISH, .) (Analysis of translocation t(14;16) (IGH/MAFB) (FISH,quantitative))	9850
BCR/ABL - t(9;22), BCR/ABL - . (Analysis of chimeric gene BCR-ABL - t(9;22), assessment of the BCR-ABL gene transcript type, PCR, qualitative)	2260
12p (FISH, .) (Analysis of 12p deletion (FISH, quantitative))	9850
BCR-ABL (FISH, .) (Analysis of chimeric gene BCR-ABL, FISH, quantitative)	9850
BCL2 (FISH, .) (Analysis of BCL2 gene rearrangements on paraffin slides (FISH Histology, quantitative))	13570
PDGFR?(FISH, .) (Analysis of gene rearrangements PDGFR? (FISH, quantitative))	9850
FGFR1 (FISH, .) (Analysis of gene rearrangements FGFR1 (FISH, quantitative))	9850
E2A/PBX1 - t(1;19) (, .) (Analysis of chimeric gene E2A/PBX1 - t(1;19) (PCR, qualitative))	2260
BRAF (V600E) (,)	7790
5 (FISH, .) (Analysis of chromosome 5 rearrangements (FISH, quantitative))	9850
t(4;14)(p16;q32) (FISH, .) (Analysis of translocation t(4;14)(p16;q32) (FISH, quantitative))	9850
t(14;16) (IGH/MAFB) (FISH, .) (Analysis of translocation t(14;16) (IGH/MAFB) (FISH,quantitative))	9850
BCR/ABL - RQ (.) (Analysis of the BCR/ABL relative expression, RQ-PCR, quantitative)	4390
() (Cytogenetic analysis of bone marrow (karyotype))	7020
FIP1L1/PDGFR?(FISH, .) (Analysis of chimeric gene FIP1L1/PDGFR? (FISH, quantitative))	9850
MLL (FISH, .) (Analysis of MLL gene rearrangements (FISH, quantitative))	9850
7 (FISH, .) (Analysis of chromosome 7 rearrangements (FISH, quantitative))	9850
, 13 - (del(13), -13) (FISH, .) (Analysis of chromosome 13 monosomy, deletion - (del(13), -13) (FISH,quantitative))	9850
12 JAK2 (, .) (Analysis of JAK2 Exon 12 mutations (PCR qualitative))	4390
BCL2 t(14;18)(q32;q21),t(2;18)(p11;q21),t(18;22)(q21;q11) (FISH, .) (Analysis of BCL2 gene rearrangements t(14;18)(q32;q21),t(2;18)(p11;q21),t(18;22)(q21;q11) (FISH, quantitative))	9850
BCR-ABL (.) (BCR-ABL1 Mutation Analysis using direct Sanger sequencing, qualitative)	8760
1 (FISH, .)	12970
3q (FISH, .) (Analysis of 3q rearrangements (FISH, quantitative))	9850
RUNX1/RUNX1T1 -t(8;21) (, .) (Analysis of chimeric gene RUNX1/RUNX1T1 -t(8;21) (PCR, qualitative))	2260
20q (FISH, .) (Analysis of 20q deletion (FISH, quantitative))	9850
MYC (t(8;14)(q24;q32)-t(2;8)(p11;q24), t(8;22)(q24;q11)) (FISH, .) (Analysis of MYC gene rearrangements (t(8;14)(q24;q32)-t(2;8)(p11;q24), t(8;22)(q24;q11) (FISH, quantitative))	9850
CALR (, .) (Analysis of CALR gene mutations, deletions, insertions, PCR, qualitative)	4390
IGH (FISH, .) (Analysis of IGH gene rearrangements (FISH, quantitative))	9850
t(2;5)(p23;q35) (FISH, .) (Analysis of translocation t(2;5)(p23;q35) (FISH, quantitative))	9850
:	
	1200
() (Additional research participant (child or mother or father))	5730

(3) (Urgent Establishment of Biological Relationship for One Parent at Indisputable Relationship of Another (3 Persons))		38030
(2) (Urgent Establishment of Biological Relationship for One Parent in Absence of Another (2 Persons))		38030
(2) (Establishment of Biological Relationship for One Parent in Absence of Another (2 Persons))		16170
(3) (Establishment of Biological Relationship for One Parent at Indisputable Relationship of Another (3 Persons))		18080
(Koprogramma, Stool)		
		340
		3690
		5570
(Fecal Calprotectin)		2380
		3220
-1- (Alpha-1-Antitrypsin, Feces)		1570
		1330
		230
() (PRO Stool, Helminth Eggs)		280
		1800
(), FOB Gold (Quantitative Immunochemical Fecal Occult Blood, Test FOB Gold)		650
1 (1), 1 (Elastase 1, E1)		2520
() (Stool Sugars, Reducing Substances, Fecal)		560
(PRO Stool)		280
(), (nterobiasis, Spatula)		260
(Stool osmotic gap)		1150
-10 (-10) (Interleukin 10, IL-10)		
		1850
-6 (-6) (Interleukin 6, IL-6)		
		1850
-? (-?) (Tumor Necrosis Factor Alpha, TNF-?, Cachectin)		
		1850
-1? (-1?) (Interleukin 1 Beta, IL-1)		
		1850
-8 (-8) (Interleukin 8, IL-8)		
		1850
IgE:		
, IgE (Food Allergy Panel, IgE)		3670
, IgE (Celery, IgE, F85)		440
, IgE (Milk, IgE, F2)		440
(f96), IgE, ImmunoCAP (Avocado, Persea americana, IgE, ImmunoCAP)		720
, IgE (Chicken Meat, IgE, F83)		440
(f244) IgE, ImmunoCAP		720
, IgE (Pineapple, IgE, F210)		440
, IgE (Grapefruit, IgE, F209)		440
-	, IgE (Beta Lactoglobulin, IgE, F77)	440
, IgE (Egg Yolk, IgE, F75)		440
(g4) IgE, ImmunoCAP		720
, IgE (Shrimp, IgE, F24)		440
, IgE (Rice, IgE, F9)		440
, IgE (Strawberry, IgE, F44)		440

, IgE (Apple, IgE, F49)	440
, IgE (Pork, IgE, F26)	440
, IgE (Lamb, IgE, F88)	440
, IgE (Tomato, IgE, F25)	440
, IgE (Baker's Yeast, IgE, F45)	440
, IgE (Potato, IgE, F35)	440
, IgE (Lemon, IgE, F208)	440
, IgE (Peach, IgE, F95)	440
3: , IgE (FP73 (F26, F27, F83, F88), Food Panel: Pork, Beef, Chicken Meat, Lamb, IgE)*	950
" 2"	1745
, IgE (Casein, IgE, F78)	440
, IgE (Kiwi Fruit, IgE, F84)	440
, IgE (Cabbage, IgE, F216)	440
, IgE (Codfish, IgE, F3)	440
, IgE (Wheat, IgE, F4)	440
1: , IgE (FP15 (F33, F49, F92, F95), Food Panel: Orange, Banana, Apple, Peach, IgE)*	950
, IgE (Carrot, IgE, F31)	440
, IgE (Common Millet, IgE, F55)	440
, IgE (Banana, IgE, F92)	440
, IgE (Soybean, IgE, F14)	440
, IgE (Chocolate, IgE, F105)	440
, IgE (Egg White, IgE, F1)	440
2: , IgE (FP50 (F84, F91, F92, F210), Food Panel: Kiwi Fruit, Mango, Banana, Pineapple, IgE)*	950
, IgE (Pumpkin, IgE, F225)	440
, IgE (Hazelnut, IgE, F17)	440
, IgE (Orange, IgE, F33)	440
, (e3) IgE, ImmunoCAP (f329), IgE, ImmunoCAP (Watermelon, Citrullus lanatus, IgE, ImmunoCAP)	720
(f5) IgE, ImmunoCAP	720
, IgE (Beef, IgE, F27)	440
, IgE (Oat, IgE, F7)	440
" 1"	1745
, IgE (Buckwheat, IgE, F11)	440
, IgE (Brewer's Yeast, IgE, F403)	520
, IgE (Crab, IgE, F23)	440
, IgE (Peanut, IgE, F13)	440
, IgE (Mango, IgE, F91)	440
(Ca) (Calcium (Ca), air)	1180
(Co) (Cobalt (Co), air)	1180
(Zr) (Zirconium (Zr), air)	1180
(Mg) (Magnesium (Mg), air)	1180
(Be) (Beryllium (Be), air)	1180
(Pb) (Lead (Pb), air)	1180
(Mo) (Molybdenum (Mo), air)	1180

(Al)	(Aluminum (Al), air)	1180
(Hg)	(Mercury (Hg), air)	1180
(Mn)	(Manganese (Mn), air)	1180
(Se)	(Selenium (Se), air)	1180
(V)	(Vanadium (V), air)	1180
(Si)	(Silica (Si), air)	1180
(Rb)	(Rubidium (Rb), air)	1180
(Bi)	(Bismuth (Bi), air)	1180
(P)	(Phosphorus (P), air)	1180
()	()	680
(Cu)	(Copper (Cu), air)	1180
(Sb)	(Antimony (Sb), air)	1180
(I)	(Iodine (I), air)	1180
(Ba)	(Barium (Ba), air)	1180
(B)	(Boron (B), air)	1180
(La)	(Lanthanum (La), air)	1180
(Fe)	(Iron (Fe), air)	1180
(Ag)	(Silver (Ag), air)	1180
(Cr)	(Chromium (Cr), air)	1180
(Sr)	(Strontium (Sr), air)	1180
(W)	(Tungsten, Wolframium (W), air)	1180
(Na)	(Sodium (Na), air)	1180
(Pt)	(Platinum (Pt), air)	1180
(Ge)	(Germanium (Ge), air)	1180
(As)	(Arsenic (As), air)	1180
(Cd)	(Cadmium (Cd), air)	1180
(K)	(Potassium (K), air)	1180
(Ni)	(Nickel (Ni), air)	1180
(Zn)	(Zinc (Zn), air)	1180
(Sn)	(Tin (Sn), air)	1180
(Li)	(Lithium (Li), air)	1180
(Au)	(Gold (Au), air)	1180
(Tl)	(Thallium (Tl), air)	1180
(Ga)	(Gallium (Ga), air)	1180

IgG	() (Extractable Nuclear Antigen, ENA, Anti-Ribonucleoprotein Antibodies, Anti-RNP)	1120
	(Scl-70, ENP-A, CENP-B, RP11, RP155, NOR90, Th/To, PM-Scl100, PM-Scl75, Ku, PDGFR, Ro-52), (Scleroderma (Systemic Sclerosis) Antibody Panel: Anti-Scl-70, ENP-A, CENP-B, RP11, RP155, NOR90, Th/To, PM-Scl100, PM-Scl75, Ku, PDGFR, Ro-52, Immunoblotting)	4010
	(), (Anti-Nuclear Antibodies, ANA, Screening)	470
	(, HEp-2 (, HEp-2) (Antinuclear Antibodies, ANA, Hep-2 Substrate, ANA-Hep2, Fluorescent Anti-Nuclear Antibodies detection, FANA, iters)	1150
	(Sm, RNP/Sm, SS-A (60), SS-A (52), SS-B, Scl-70, PM-Scl, PCNA, CENT-B, dsDNA, Histone, Nucleosome, Rib P, AMA-M2, Jo-1), (ANA: Anti-Sm, RNP/Sm, SS-A (60 kD), SS-A (52 kD), SS-B, Scl-70, PM-Scl, PCNA, CENT-B, dsDNA, Histone, Nucleosome, Rib P, AMA-M2, Anti-Jo-1, Immunoblotting)	3190

IgG (Anti-Nuclear Antibodies, ANA, IgG, Screening)		1120
		990
IgG (Double-Stranded (Native) DNA IgG Antibodies, Anti-dsDNA IgG)		570
IgG		1570
(Nechiporenko's Urine Test)		
(Sulkowitch Urine Calcium Test)		230
(Complete Urinalysis, Microscopic Examination)		130
(Hepatitis C Virus, HCV)		
(Hepatitis C Virus (HCV) RNA, Quantitative PCR, Genotyping (Types 1, 2, 3))		230
(Interleukin 28 Beta IL28B, Genotyping (Study of Genetic Markers Determining Effectiveness of Treatment of Chronic Hepatitis C in Interferon and Ribavirin))		130
(CITO), (HCV RNA, Plasma, Quantitative)*		230
(Hepatitis C Virus (HCV) RNA, Ultrasensitive PCR)		20940
IgM IgG (Anti-HCV Total (IgG + IgM))*		3050
IgG (Anti-HCV IgG, Immunoblot)		360
(HCV RNA, Serum, Qualitative)*		5110
(HCV RNA, Serum, Quantitative, PCR)*		630
(Hepatitis C Virus (HCV) RNA, Plasma, Genotyping, Subtypes (Types 1 (Subtypes 1a, 1b), 2, 3))*		3140
(HCV RNA, Plasma, Quantitative)*		840
(Staphylococcus aureus)		
(Staphylococcus aureus), (Staphylococcus aureus (Methicillin-Resistant Staphylococcus aureus – MRSA) Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)		980
(Staphylococcus aureus), (Staphylococcus aureus (Methicillin-Resistant Staphylococcus aureus – MRSA) Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)		1950
(Staphylococcus aureus) (Staphylococcus aureus (Methicillin-Resistant Staphylococcus aureus – MRSA) Culture. Bacteria Identification)		650
(Staphylococcus aureus), (Staphylococcus aureus Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)		980
(Staphylococcus aureus), (Staphylococcus aureus Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)		1950
(Staphylococcus aureus) (Staphylococcus aureus Culture. Bacteria Identification)		650
(Staphylococcus aureus), (Staphylococcus aureus Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		800
(Staphylococcus aureus), (Staphylococcus aureus (Methicillin-Resistant Staphylococcus aureus – MRSA) Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		800
(Herpes simplex virus, HSV-1, HSV-2)		
(HSV-1, 2 DNA, Urine)*		250
(HSV-1, 2 DNA, Serum, typing)*		600

1 2 , (HSV-1, 2 DNA, Scrape of Conjunctiva Epithelial Cells)*		250
1 2 , (HSV-1, 2 DNA, Scrape of Conjunctiva Epithelial Cells, yping)*		420
1 2 , (HSV-1, 2 DNA, Urine, yping)*		420
IgG 1 2 (Anti-HSV-1, 2 IgG)		440
1 2 , Blood, yping)* (HSV-1, 2 DNA,		600
1 2 , 2 DNA, Cerebrospinal Fluid, yping)* (HSV-1,		420
1 2 , (HSV-1, 2 DNA, Exudate)*		250
1 2 , (HSV-1, 2 DNA, Scrape of Faucial Epithelial Cells, yping)*		420
Ig 1 2 (Anti-HSV-1, 2 Ig)		460
1 2 , (HSV-1, 2 DNA, Scrape of Urogenital Epithelial Cells, yping)*		420
1 2 , yping)* (HSV-1, 2 DNA, Saliva,		420
1 2 , yping)* (HSV-1, 2 DNA, Exudate,		420
1 2 , (HSV-1, 2 DNA, Blood)*		380
1 2 , (HSV-1, 2 DNA, Saliva)*		250
1 2 , DNA, Scrape of Skin Epithelial Cells)* (HSV-1, 2		250
1 2 , (HSV-1, 2 DNA, Scrape of Nasal Epithelial Cells, yping)*		420
1 2 , Cerebrospinal Fluid)* (HSV-1, 2 DNA,		250
1 2 , Prostatic Fluid, Semen)* (HSV-1, 2 DNA,		250
1 2 , 2 DNA, Prostatic Fluid, Semen, yping)* (HSV-1,		420
IgG 2 (Anti-HSV-2 IgG)		550
1 2 , (HSV-1, 2 DNA, Serum)*		380
1 2 , (HSV-1, 2 DNA, Scrape of Nasal Epithelial Cells)*		250
Anti-HSV IgG		700
1 2 , (HSV-1, 2 DNA, Scrape of Urogenital Epithelial Cells)*		250
1 2 , (HSV-1, 2 DNA, Scrape of Skin Epithelial Cells, yping)*		420
IgG 1 (Anti-HSV-1 IgG)		680
1 2 , (HSV-1, 2 DNA, Scrape of Faucial Epithelial Cells)*		250
COVID-19		
SARS-CoV-2, IgM (anti-SARS-CoV-2, IgM)		690
SARS-CoV-2-IgG- (N-, S-proteins) antibodies, IgG, qualitative)	SARS-CoV-2 (N-, S-), (Post-vaccination (EpiVacCorona Vector) SARS-CoV-2	2260
SARS-CoV-2, (Coronavirus SARS-CoV-2 RNA detection in nasopharyngeal and oropharyngeal smear)		1990
spike (S) protein (RBD), IgG, quantitative).	(S) (RBD) SARS-CoV-2, IgG (Anti-SARS-CoV-2,	1290
SARS-CoV-2, (Coronavirus SARS-CoV-2 RNA detection in nasopharyngeal and oropharyngeal smear)		1290
SARS CoV-2 (S- RBD), IgG,		1290
(S) SARS-CoV-2, IgG, qualitative. Assessment of immunity before and after vaccination)	(anti-SARS-CoV-2 S (spike) protein antibody, IgG,	890
SARS-CoV-2 (nucleocapsid protein), IgG, Abbott)	(Anti-SARS-CoV-2	690
SARS-CoV-2 (RBD), IgG (anti-SARS-CoV-2 (RBD) IgG avidity)		690

A	IgM	Mycoplasma pneumoniae (Anti-Mycoplasma pneumoniae IgM)	500
		(Mycoplasma genitalium), (Mycoplasma genitalium, DNA, Scrape of Urogenital Epithelial Cells)*	250
		(Mycoplasma hominis), (Mycoplasma hominis, DNA, Scrape of Urogenital Epithelial Cells)*	250
		(Mycoplasma pneumoniae), (Mycoplasma pneumoniae, DNA, Plasma)*	390
	Ig	Mycoplasma pneumoniae (Anti-Mycoplasma pneumoniae IgA)	610
		(Mycoplasma pneumoniae), (Mycoplasma pneumoniae, DNA, Scrape of Faucial Epithelial Cells)*	210
A	IgG	Mycoplasma pneumoniae (Anti-Mycoplasma pneumoniae IgG)	500
	Ig	Mycoplasma hominis (Anti-Mycoplasma hominis IgG)	420
		(Mycoplasma pneumoniae), (Mycoplasma pneumoniae, DNA, Sputum)*	590
		(Mycoplasma hominis), (Mycoplasma hominis, DNA, Prostatic Fluid, Semen)*	250
	IgG	Mycoplasma hominis (Anti-Mycoplasma hominis IgG)	420
		(Mycoplasma genitalium), (Mycoplasma genitalium, DNA, Prostatic Fluid, Semen)*	250
		(Mycoplasma pneumoniae), (Mycoplasma pneumoniae, DNA, Saliva)*	210
		(Mycoplasma hominis), (Mycoplasma hominis, DNA, Urine)*	250
	IgA	Mycoplasma hominis (Anti-Mycoplasma hominis IgA)	610
		(Mycoplasma genitalium), (Mycoplasma genitalium, DNA, Urine)*	250
	(g)	(Magnesium (Mg), Serum)	230
		(Ca) (Calcium Total)	190
/	/	(+ /Potassium, Na+ /Sodium, I- /Chloride, Serum)	250
		(Ca ²⁺ , c) (Ionized Calcium, Free Calcium)	360
		(P) (Phosphorus (P))	190
	()	(,)	190
		(Unsaturated Iron Binding Capacity, UIBC)	190
	(Fe)	(Iron (Fe), Serum)	190
		Helicobacter pylori () (Helicobacter pylori Associated Gastritis)*	3640
		PDGFRa	13700
	1	() (1):	1540
		PD-L1 c	16500
		PD-L1 SP263 (Ventana). (PD-L1 expression in tumor tissue by IHC using PD-L1 clone SP263 (Ventana) antibodies).	16500
		KIT	11600
		(1 + 1) (Consultation of Finished Histological Preparations (1 Glass + 1 Block))	1300
		BRCA1, BRCA2	7400
		(PAS-)	290
		ROS1	8000
	18,19,20, 21	EGFR	9900
	2,3,4	NRAS	7000
	15	BRAF	4800
	2,3,4	KRAS	7000

PD-L1 PD-L1 SP142 (Ventana). (PD-L1 expression in tumor tissue by IHC using PD-L1 clone SP142 (Ventana) antibodies).	c	16500
(MSI)		6200
HER2 ()		11600
S-100, Melan A (MART-1), HMB-45, SOX-10 (IHC verification of malignant melanoma using assessment of the expression S-100, Melan A (MART-1), HMB-45, SOX-10)*	()	18080
() (Pathology of skin biopsies)*		2030
Histochemical Study)* Helicobacter pylori () (Helicobacter pylori, Mucus,		1920
ALK		8000
(; , ; ; -)*		2200
PD-L1 PD-L1 22 3 (Dako). (PD-L1 expression in tumor tissue by IHC using PD-L1 clone 22C3 (Dako) antibodies).		24000
PDL1		7400
S-100, Melan A (MART-1), HMB-45, SOX-10 (IHC verification of malignant melanoma using assessment of the expression S-100, Melan A (MART-1), HMB-45, SOX-10)	()	18080
SCC () (Squamous Cell Carcinoma Antigen, SCCA, SCCAg)		2260
-19-9 (19-9) (Carbohydrate Antigen -19-9, Cancer Antigen-GI)		620
(Chromogranin A, CgA)		4770
- (,) (Carcinoembryonic Antigen, CEA)		570
CA-242 (242, CA-242) (Carbohydrate Antigen -242, Tumor Marker CA-242)		840
ROMA1		70
() (Neuron-Specific Enolase, NSE)		1220
PSA Total)* () (Prostate-Specific Antigen Total,		440
UBC (8 18) (Urine Bladder Cancer Antigen, Urine Bladder Cancer, UBC)		1860
(, , -2proPSA, phi)		2900
HE4 (4) (Human Epididymis Protein 4, HE4)		1020
-2- Serum) (?-2-) (eta-2-Microglobulin, BMG,		870
PSA Total) () (Prostate-Specific Antigen Total,		440
ROMA2		70
- () (?-Fetoprotein, AFP)		350
-15-3 (15-3) (Carbohydrate Antigen -15-3, Cancer Antigen -15-3)		620
-125 (125) (Carbohydrate Antigen -125, Cancer Antigen -125)		580
()*		440
CA-72-4 (72-4) (Carbohydrate Antigen -72-4, Cancer Antigen CA-72-4)		870
(Cyfra 21-1, 19) (Cytokeratin 19 Fragments, C-terminus of Cytokeratin 19, CK19 Soluble Fragments, Cyfra 21-1)		860
-2- (?-2-) (Beta-2-Microglobulin, Urine)		870
S100 (S100 rotein)		2490
()		
(Trichomonas vaginalis, DNA, Urine)*		250
Prostatic Fluid, Semen)* (Trichomonas vaginalis, DNA,		250

(Trichomonas vaginalis, DNA, Scrape of Urogenital Epithelial Cells)*		250
IgG Trichomonas vaginalis (anti-Trichomonas vaginalis IgG)		610
(Procedural services)		
examinations)**	(Blood serum derivation without further	320
		350
	(Blood sampling without further examinations)**	190
	(Buccal epithelium sampling, 2 persons)	180
(Cytological material sampling, PCR diagnosis material sampling, microbiology test material sampling)		350
	(Saliva sampling for PCR)	50
A11.12.009		200
	(Biomaterial sampling for the enterobiasis test)	70
	(Buccal epithelium sampling, 3 persons)	270
	() (capillary blood sampling)	190
	(Buccal epithelium sampling)	90
C		
	6 (1 ,1b,2,3 ,4,5 ,6)	2380
(Ureaplasma parvum)		
(Ureaplasma parvum, Effectiveness Monitoring of Treatments)		360
(INBIOFLOR ? Mycoplasma, Urogenital Screening)		480
(INBIOFLOR-Comprehensive Study of Microflora Composition of Urogenital Tract (UGT))		2780
(Bacterial Vaginosis, BV)		1540
MICROBIOCENOSIS (PCR Panel Femoflor 8)	8. (UROGENITAL TRACT	1480
(4 +): Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, (Identification of Sexually Transmitted Infections (STI) Pathogens, Chlamydia trachomatis DNA, Neisseria gonorrhoeae DNA, Trichomonas vaginalis DNA, Mycoplasma genitalium DNA, Human DNA)		930
(Mobiluncus curtisii, DNA, Scrape of Urogenital Epithelial Cells)		210
(Mycoplasma hominis, Effectiveness Monitoring of Treatments)	(Mycoplasma hominis)	360
		1700
ur alyticum) (Ureaplasma ur alyticum, Effectiveness Monitoring of Treatments)	(Ureaplasma	360
(7 +), (Identification of Sexually Transmitted Infections (STI) Pathogens, Scrape of Urogenital Epithelial Cells)*		1350
MICROBIOCENOSIS (PCR Panel Femoflor 16)	16. (UROGENITAL TRACT	2100
		2000
MICROBIOCENOSIS, Screening (PCR Panel Femoflor Screen))	(UROGENITAL TRACT	1850
		1240
		3820
(As) (Arsenic (As), Nails)		1180
(Pb) (Lead (Pb), Nails)		1180
(Sb) (Antimony (Sb), Nails)		1180
(Cr) (Chromium (Cr), Nails)		1180

Types (6, 11, 16, 18) Screening)	4 : 6, 11, 16, 18 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 4	550
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68))	14 : 16,	350
39, 45, 51, 52, 56, 58, 59, 66, 68 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)*	14 : 16, 18, 31, 33, 35,	350
Epithelial Cells, 3 Types (6, 11, 44)	3 : 6, 11, 44 + (HPV DNA, Scrape of Rectal	350
Epithelial Cells, 2 Types (16, 18))	16 18 + (HPV DNA, Scrape of Urogenital	350
(6, 11, 44))	3 : 6, 11, 44 (HPV DNA, Scrape of Faucial Epithelial Cells, 3 Types	350
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)	() 14 : 16, 18,	900
Epithelial Cells, 3 Types (6, 11, 44)	3 : 6, 11, 44 + (HPV DNA, Scrape of Urogenital	350
39, 45, 51, 52, 56, 58, 59, 66, 68 + (HPV DNA, Scrape of Faucial Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)*	14 : 16, 18, 31, 33, 35,	350
52, 53, 56, 58, 59, 66, 68, 73, 82 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 21 Types (6, 11, 16, 18, 26, 31, 33, 35, 39, 44, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82))	21 : 6, 11, 16, 18, 26, 31, 33, 35, 39, 44, 45, 51,	2450
39, 45, 51, 52, 56, 58, 59, 66, 68 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)*	14 : 16, 18, 31, 33, 35,	350
(Candida albicans, DNA, Exudate)*		250
(Candidiasis, Typing)		670
(Candida, Cryptococcus) (Yeast Culture. Identification and Antimycotic Susceptibility testing)		690
(Candidiasis, Screening)		360
Semen)* (Candida albicans, DNA, Prostatic Fluid,		250
(Candida albicans, DNA, Scrape of Rectal Epithelial Cells)*		250
(Candida albicans, DNA, Scrape of Faucial Epithelial Cells)*		250
Candida albicans, IgG (M5) (M5 Candida albicans, IgG)		520
(Candidiasis, Screening and Typing)		920
A IgG Candida albicans (Anti-Candida albicans IgG)		710
(Candida albicans, DNA, Urine)*		250
(Candida albicans, DNA, Scrape of Skin Epithelial Cells)*		250
(Candida albicans, DNA, Scrape of Urogenital Epithelial Cells)*		250
(Candida albicans, DNA, Saliva)*		250
()		1670

(Upper Respiratory Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1980
(Eye Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	1340
(Eye Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	2240
(Stool Culture with Bacteria Identification and Antibiotic+ Bacteriophage Susceptibility Testing)	1460
(Stool Culture, Pathogenic Intestinal and Conditionally Pathogenic Microflora. Bacteria Identification and Antibiotic Susceptibility Testing)	1380
(Breast Milk Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	980
()	1570
(Ear Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	2240
(Eye Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	1160
(Breast Milk Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1950
(Punctate Fluid Culture. Bacteria Identification and Antibiotic Susceptibility Testing)	830
(Wound/Pus/Aspirate/Tissue Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	980
(Bile Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	1040
(Anaerobic Culture. Bacteria Identification and Antibiotic Susceptibility Testing)	1400
(Sputum and Tracheobronchial washings Culture. Bacteria Identification and Antibiotic Susceptibility Testing, Microscopy)*	1080
(Urine Culture. Bacteria Identification, Antibiotic susceptibility and Bacteriophage Efficiency Testing)*	980
A12.20.001	450
(Ureaplasma spp. Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	680
(Breast Milk Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	800
(Genitourinary Tract Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	2240
(Wound/Pus/Aspirate/Tissue Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	800
(Mycoplasma hominis Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	770
(Genitourinary Tract Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	1160
(Ear Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	1340
(Urine Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1950
(Upper Respiratory Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	1020

(Ear Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	1160
(Vaginal Biocenosis: Bacteriophage and Antimycotic Susceptibility Testing (Gram Stain, Bacterioscopic Examination of Smear))*	1500
(Wound/Pus/Aspirate/Tissue Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1950
(Bile Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	2150
(Breast Milk Culture. Bacteria Identification)	650
(Genitourinary Tract Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	1340
(Adenovirus), (Adenovirus. One Step Rapid Immunohromotographic Assay)	870
(Urine Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	800
(Sputum and Tracheobronchial washings Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing, Microscopy)*	2170
(Helicobacter pylori), (Helicobacter pylori. One Step Rapid Immunohromotographic Assay)	870
(Upper Respiratory Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	830
(Punctate Fluid Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1980
(Stool Culture, Pathogenic Intestinal and Conditionally Pathogenic Microflora, Bacteria Identification)	1190
6 ()	2180
1 ()	2180
12 () (Cobalamin)	630
(-) (Vitamin E, alpha-Tocopherol, Serum)	2180
5 ()	2180
1,25-D3 (1,25-dihydroxivitamin D3)	1900
3 ()	2180
25(OH)D2 25(OH)D3, (- /)	5460
(Folic Acid)	870
() (Vitamin A, Retinol, Serum)	2180
1 () (Vitamin K1, Phylloquinone, Serum)	2180
7, ()	2180
12 (, Active-B12, Holotranscobalamin)	1250
-	2180
2 ()	2180
()	2180
	2180
LG11 CASPR2 (), IgG, (VGKC-associated proteins LG11 and CASPR2 antibodies, serum)	5600
, IgG, (Neuronal antibodies, IgG, Indirect immunofluorescence (IIF))	3010
(), o (Acetylcholine Receptor Antibodies, Anti-AChR, Total)	5210

IgG, NMDA, CASPR, LGI, AMPA1, AMPA2, GABAR1	12370
IgG () (Anti-Skeletal Muscle Antibodies, AStMA, IgG)	1110
NMDA, IgG, (-NMDAR IgG, N-methyl-D-Aspartate Receptor Antibodies, CSF)	2760
IgG (- : Mi-2, Ku, PM-Scl 100/75; Jo1 PL-7 PL-12 EJ OJ; SRP, SSA (Ro52)) (Myositis-Specific Panel)	3670
IgG IgM (- : GM1; GM2-GM3-GM4; GD1a, GD1b, GD2-GD3, GT1a, GT1b, GQ1b,), (Anti-GM1 Antibodies, Anti-GQ1b Antibodies, Anti-Ganglioside antibodies, Ganglioside Antibodies Panel, Total)	5210
Critidia luciliae, IgG, (Critidia luciliae indirect fluorescent test (CLIFT))	1150
IgG, (Anti-myelin antibody, IgG, IF)	1340
IgA, IgG, IgM 4, (NMO) (Aquaporin-4 Receptor Antibodies, anti-AQP4, Neuromyelitis Optica, NMO, IgA, IgG, IgM, Total)	2600
IgG () (Oligoclonal IgG, Cerebrospinal Fluid (CSF), Serum)	3990
(Muscle-specific tyrosine kinase (MuSK) antibody) (-MuSK)	4980
IgG, NMDA, CASPR, LGI, AMPA1, AMPA2, GABAR1	12500
LGI1 CASPR2 (), IgG, (VGKC-associated proteins LGI1 and CASPR2 antibodies, CSF)	5600
GAD (), IgG, (Anti-GAD (glutamic acid decarboxylase), IgG, CSF)	1890
IgG (- : Hu (ANNA1), Yo-1 (PCA1), CV2, 2, Ri (ANNA2),) (Anti-Neuronal Antibodies, Blot-Line (Hu (ANNA1), Yo-1 (PCA1), CV2, 2, Ri (ANNA2), Amphiphysin))	5210
IgG NMDA (N- -D-) (N-Methyl-D-Aspartate Receptor Antibodies IgG)	3990
Complement (CH50) : (CH50) (Functionality Test of	1340
1- (C1-Esterase Inhibitor, 1-INH)	1960
4 (Complement Component C4)	360
3 (Complement Component C3)	360
IgG (Anti-Rubella IgG, Immunoblot)	5110
Ig (Anti-Rubella Ig)	490
Anti-Rubella IgG	970
(Rubella virus, RNA)	590
IgG (Anti-Rubella IgG)	360
B (Anti-HBc IgM, IgG, Antibodies to Hepatitis B Core Antigen; HBcAb, Total, HBV Core Total Antibodies (IgG + IgM))	
HBs- (HBs- B, (HBsAg, Hepatitis Surface Antigen, Quantitative)	1320
HB - (Hepatitis Be Antigen, HBeAg)	510
IgM HB-core B (Anti-HBc IgM Antibodies to Hepatitis B Core Antigen; HBV Core Antibodies IgM)	630
B, (HBV DNA, Serum, Quantitative)*	3410
B, (HBV DNA, Serum, Qualitative)*	380
HBs- (Anti-HBs, HBsAb)	570
HB - (Anti-HBe, HBeAb)	470

HBs- (HBs- (HBsAg, Hepatitis Surface Antigen, Qualitative)	B, (HBsAg, Hepatitis Surface Antigen, Qualitative)	240
- 2 (2-Hour Oral Glucose Tolerance Test, OGTT, Glucose and C-Protein Concentration (Fasting and 2 Hours after Load), Venous Blood)		1390
A09.05.023		130
(Lactate)		520
(Fructosamine)		810
HbA1 (HbA1, Glycated Hemoglobin, GHB)		460
) Oral Glucose Tolerance Test, Plasma, OGTT, Pregnancy		900
- 2 (2-Hour Oral Glucose Tolerance Test, OGTT, Glucose Concentration (Fasting and 2 Hours after Load), Venous Blood)		610
- () (C-Reactive Protein, CRP)		310
- (- ,) (Antistreptolysin-O, ASO)		340
-1- (1), (Alpha-1-Antitrypsin, A1AT, AAT, Phenotyping)		2360
(-) N- (NT-proBNP, N-Terminal Pro-brain Natriuretic Peptide, Pro-B-Type Natriuretic Peptide)		2560
(Ferritin)		460
- (Carbohydrate-Deficient Transferrin with results on an electrophoregram (CDT))		3020
25 () (Hepcidin 25, bioactive)		5970
ST2 (ST2, sST2,) (Soluble ST2 (Heart Failure's biomarker))		2490
() (Transferrin)		440
(Myoglobin)		520
-2- (Alpha-2-Macroglobulin, ?2-Macroglobulin, A2M)		450
IgG () Chlamydia trachomatis IgG		520
() (Rheumatoid Factor, RF)		340
-I (Troponin-I)		570
- ()		540
(Ceruloplasmin)		590
(Haptoglobin)		580
-1- (1), (Alpha-1-Antitrypsin, A1AT, AAT, Concentration)		1260
- (Carbohydrate-Deficient Transferrin, CDT)		2810
(, Soluble Transferrin Receptor, sTfR)		1700
(Eosinophil Cationic Protein, ECP)		790
(Ureaplasma parvum), (Ureaplasma parvum, DNA, Urine)*		250
(Ureaplasma arvum), (Ureaplasma parvum, DNA, Prostatic Fluid, Semen)*		250
IgG Ureaplasma urealyticum (nti-Ureaplasma urealyticum IgG)		610
(Ureaplasma urealyticum) (-960), (Ureaplasma urealyticum (T-960), DNA, Scrape of Urogenital Epithelial Cells)*		250
IgA Ureaplasma urealyticum (nti-Ureaplasma urealyticum IgA)		610
(Ureaplasma urealyticum + Ureaplasma arvum), (Ureaplasma urealyticum + Ureaplasma arvum, DNA, Prostatic Fluid, Semen)*		250
(Ureaplasma urealyticum + Ureaplasma arvum), (Ureaplasma urealyticum + Ureaplasma arvum, DNA, Urine)*		250
(Ureaplasma arvum), (Ureaplasma parvum, DNA, Scrape of Urogenital Epithelial Cells)*		250

(Ureaplasma urealyticum) (-960), (Ureaplasma urealyticum (T-960), DNA, Prostatic Fluid, Semen)*		250
(Ureaplasma urealyticum + Ureaplasma arvum), (Ureaplasma urealyticum + Ureaplasma arvum, DNA, Scrape of Urogenital Epithelial Cells)*		250
(Ureaplasma urealyticum) (-960), urealyticum (T-960), DNA, Urine)*	(Ureaplasma	250
-		
A (RSV) IgG	- (Anti-Respiratory Syncytial Virus	710
A (RSV) IgM	- (Anti-Respiratory Syncytial Virus	710
-		
(Genes F2, F5)	e (F2, F5) (Risk of Oral Contraceptives, Ocs	2730
-	e (F2, F5) () (Risk of Oral Contraceptives, OCS (Genes F2, F5) (without Description))	2450
	, 6 (AZF) ()	3560
MTHFR, MTRR, MTR, F2, F5)	(MTHFR, MTRR, MTR, F2, F5) (Preparation for Surgery (Genes	8010
-	(MTHFR, MTRR, MTR, F2, F5) () (Preparation for Surgery (Genes MTHFR, MTRR, MTR, F2, F5) (without Description))	7180
IgG:		
(F24), -	IgG (Shrimp, IgG, F24)	520
(F9), -	IgG (Rice, IgG, F9)	520
Food Panel: Orange, Banana, Apple, Peach, IgG)*	1: , IgG (FP15 (F33, F49, F92, F95),	950
(F84), -	IgG (Kiwi Fruit, IgG, F84)	520
(F11), -	IgG (Buckwheat, IgG, F11)	520
(F3), -	IgG (Codfish, IgG, F3)	520
Food Profile, IgG)	3: , IgG (FP73 (F26, F27, F83, F88), Food Panel: Pork, Beef, Chicken Meat, Lamb, IgG)* G (IgG) (Basic	14400
(F44), -	IgG (Strawberry, IgG, F44)	520
(F7), -	IgG (Oat, IgG, F7)	520
(F105), -	IgG (Chocolate, IgG, F105)	520
	(fx21) IgE, ImmunoCAP	1250
(F4), -	IgG (Wheat, IgG, F4)	520
-	, IgG (Beta Lactoglobulin, IgG, F77)	520
(F2), -	IgG (Milk, IgG, F2)	520
(F25), -	IgG (Tomato, IgG, F25)	520
(F55), -	IgG (Common Millet, IgG, F55)	520
	, IgG (Pineapple, IgG, F210)	520
	, IgG (Lamb, IgG, F88)	520
(F26), -	IgG (Pork, IgG, F26)	520
(F208), -	IgG (Lemon, IgG, F208)	520
	, IgG (Banana, IgG, F92)	520
(F75), -	IgG (Egg Yolk, IgG, F75)	520
(F1), -	IgG (Egg White, IgG, F1)	520
(F83), -	IgG (Chicken Meat, IgG, F83)	520
(F35), -	IgG (Potato, IgG, F35)	520
	, IgG (Orange, IgG, F33)	520

(F209),	-	IgG (Grapefruit, IgG, F209)	520
(F91),	-	IgG (Mango, IgG, F91)	520
,		IgG (Peanut, IgG, F13)	520
Panel: Kiwi Fruit, Mango, Banana, Pineapple, IgG)*			1300
(F225),	-	IgG (Pumpkin, IgG, F225)	520
(F14),	-	IgG (Soybean, IgG, F14)	520
(F31),	-	IgG (Carrot, IgG, F31)	520
(F27),	-	IgG (Beef, IgG, F27)	520
(F45),	-	IgG (Baker's Yeast, IgG, F45)	520
(F216),	-	IgG (Cabbage, IgG, F216)	520
(F403),	-	IgG (Brewer's Yeast, IgG, F403)	520
(F17),	-	IgG (Hazelnut, IgG, F17)	520
(F78),	-	IgG (Casein, IgG, F78)	520
(F95),	-	IgG (Peach, IgG, F95)	520
(F49),	-	IgG (Apple, IgG, F49)	520
- 6			
		IgG 6 (Anti-HHV-6 IgG)	610
		6 (HHV-6 DNA, Saliva)*	250
		6 (HHV-6 DNA, Scrape of Urogenital Epithelial Cells)*	250
		6 (HHV-6 DNA, Prostatic Fluid, Semen)*	250
		6 (HHV-6 DNA, Scrape of Nasal Epithelial Cells)*	250
		6 (HHV-6 DNA, Urine)*	250
		6 (HHV-6 DNA, Cerebrospinal Fluid)*	250
		6 (HHV-6 DNA, Exudate)*	250
		6 (HHV-6 DNA, Blood)*	380
		6 (HHV-6 DNA, Scrape of Faucial Epithelial Cells)*	250
		6 (HHV-6 DNA, Serum)*	380
()			
		(Chlamydia pneumoniae), (Chlamydia pneumoniae), DNA, Saliva)*	390
		(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Prostatic Fluid, Semen)*	250
		IgG () Chlamydia trachomatis (Anti-cHSP60 IgG)	530
A		IgA Chlamydia trachomatis (Anti-Chlamydia trachomatis IgA)	490
		(Chlamydia pneumoniae), (Chlamydia pneumoniae, DNA, Plasma)*	590
A		IgG Chlamydia pneumoniae (Anti-Chlamydia pneumoniae IgG)	510
		IgM Chlamydia trachomatis (Anti-Chlamydia trachomatis IgM)	510
		(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Rectal Epithelial Cells)*	250
		(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Urogenital Epithelial Cells)*	250
A		IgG Chlamydia trachomatis (Anti-Chlamydia trachomatis IgG)	490
		(Helicobacter pylori, DNA, Biopsies of Gastric Mucosa and/or Duodenum, PCR)	2120
		(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Conjunctiva Epithelial Cells)*	250
A		IgA Chlamydia pneumoniae (Anti-Chlamydia pneumoniae IgA)	610

(Chlamydia pneumoniae), DNA, Sputum)*	(Chlamydoghila pneumoniae,	790
A IgM Chlamydoghila pneumoniae (Anti-Chlamydoghila pneumoniae IgM)		510
(Chlamydia trachomatis), Urine)*	(Chlamydia trachomatis, DNA,	250
(Chlamydia trachomatis), trachomatis, DNA, Cerebrospinal Fluid)*	(Chlamydia	250
(Chlamydia trachomatis), Exudate)*	(Chlamydia trachomatis, DNA,	250
(Chlamydia trachomatis), trachomatis, DNA, Synovial Fluid)*	(Chlamydia	460
(Chlamydia pneumoniae), (Chlamydoghila pneumoniae, DNA, Scrape of Faucial Epithelial Cells)*		390
(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Faucial Epithelial Cells)*		250
Prostatic Fluid, Semen)*	(Treponema pallidum, DNA,	250
(Treponema pallidum, DNA, Scrape of Urogenital Epithelial Cells)*		250
(Treponema pallidum, DNA, Urine)*		250
DNA, Cerebrospinal Fluid)*	(Treponema pallidum,	250
(Treponema pallidum, DNA, Serum)*		370
(Treponema pallidum, DNA, Secretion)*		250
A IgM IgG Treponema pallidum, IgG, Total)	(Anti-Treponema pallidum IgM,	380
pallidum, DNA, Scrape of Skin Epithelial Cells)*	(Treponema	250
(Treponema pallidum, DNA, Scrape of Faucial Epithelial Cells)*		250
A IgG Treponema pallidum, (Anti-Treponema pallidum IgG, Immunoblot)		1790
(Treponema pallidum, DNA, Scrape of Conjunctiva Epithelial Cells)*		250
A IgM Treponema pallidum (Anti-Treponema pallidum IgM)		810
RPR – est)	(Syphilis RPR (Rapid Plasma Reagens), nticardiolipin	210
A IgM Treponema pallidum, (Anti-Treponema pallidum IgM, Immunoblot)		1790
(Testosterone)		350
- (-SO4, Dehydroepiandrosterone sulfate, DHEA-S)		350
17- (17-) (17-Ketosteroids, Urine)		1830
() (Sex Hormone-Binding Globulin, SHBG)		360
(Androstenedione)		1000
17- - (17-Hydroxyprogesterone, 17-OHP)		490
(Free Testosterone)		870
() (Androstanediol Glucuronide, 3?-Androstanediol Glucuronid, 3?-diol G)		1050
() (Dih drotestosterone, DHT)		1300
()		260
(Protein, random urine, with creatinine and protein/creatinine ratio calculation)		530
(Magnesium, random urine, with creatinine and magnesium/creatinine ratio calculation)		280
() (Phosphorus, random urine, with creatinine and phosphorus/creatinine ratio calculation)		290

(Oxalates, random urine, with creatinine and oxalate/creatinine ratio calculation)		1350
(Albumin, random urine, with creatinine and albumin/creatinine ratio calculation, UACR)		450
(Calcium, random urine, with creatinine and calcium/creatinine ratio calculation)		200
(Urine Creatinine)		50
IgE:		
, IgE (Cockroach, IgE, I6)		440
, IgE (Dog Epithelium, IgE, E2)		440
, IgE (Sheep Epithelium, IgE, 81)		440
, IgE (Budgerigar Feathers, IgE, 78)		440
, IgE (EP70 (E6, E82, E84, E87, E88), Animal Panel: Guinea Pig Epithelium, Rabbit Epithelium, Hamster Epithelium, Rat, Mouse, IgE)*		950
, IgE (Guinea Pig Epithelium, IgE, 6)		440
, IgE (Cat Dander-Epithelium, IgE, E1)		440
, IgE (Chicken Feathers, IgE, 85)		440
-		
1 2 1 2 (HIV Ag/Ab Combo)		290
-1, (HIV RNA, Plasma)*		12940
(Everolimus)		
(Cyclosporine, Cyclosporine A, Sandimmune)		950
, (Teriflunomide, Leflunomide metabolite)		3300
(Levetiracetam, Keppra®)		3400
(carbamazepine, Tegretol)		2620
, (Mitotane, o, p?-DDD, plasma)		3300
(Phenytoin)		1160
(FK506, Advagraf, Prograf, Protopic, Tacrosel)		1430
(Lamotrigine)		3400
(Acidum Valproicum, Depakin, Convulexs)		810
(Phenobarbitalum)		2620
()		
Prostatic Fluid, Semen)* (Neisseria gonorrhoeae, DNA,		250
(Neisseria gonorrhoeae, DNA, Scrape of Rectal Epithelial Cells)*		250
Fluid)* (Neisseria gonorrhoeae, DNA, Synovial		460
(Neisseria gonorrhoeae,), (GC, Neisseria gonorrhoeae Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		900
gonorrhoeae, DNA, Scrape of Conjunctiva Epithelial Cells)* (Neisseria		250
gonorrhoeae, DNA, Scrape of Faucial Epithelial Cells)* (Neisseria		250
, (Neisseria gonorrhoeae, DNA, Urine)*		250
(Neisseria gonorrhoeae, DNA, Scrape of Urogenital Epithelial Cells)*		250
(Lactobacillus spp., DNA, Scrape of Urogenital Epithelial Cells)*		
		320

Clostridium difficile (Toxin A and B Clostridium difficile. One step rapid immunochromatographic assay)		1200
(Clostridium difficile,) (Clostridium difficile Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		1250
?		
()		1000
() (Cytological Examination: Cervix, Pap-test)		1000
IgE:		
/H1-Greer, IgE (House Dust - Greer, IgE, H1)		440
Penicillium notatum, IgE (Penicillium notatum, IgE, M1)		440
Candida albicans, IgE (Candida albicans, IgE, M5)		440
Dermatophagoides pteronyssinus (D1), IgE (Dermatophagoides pteronyssinus, IgE, D1)		440
Aspergillus fumigatus, IgE (Aspergillus fumigatus, IgE, M3)		440
Alternaria tenuis, IgE (Alternaria tenuis, IgE, M6)		440
Dermatophagoides farinae (D2), IgE (Dermatophagoides farinae, IgE, D2)		440
: Penicillium notatum, Cladosporium herbarum, Aspergillus fumigatus, Candida albicans, Alternaria tenuis, IgE (MP1 (M1, M2, M3, M5, M6), Mold Panel 1: Penicillium notatum, Cladosporium herbarum, Aspergillus fumigatus, Candida albicans, Alternaria tenuis, IgE)*		950
Cladosporium herbarum, IgE (Cladosporium herbarum, IgE, M2)		440
IgG:		
Dermatophagoides farinae (D2), - IgG (Dermatophagoides farinae, IgG, D2)		520
/Greer (1), - IgG (House Dust - Greer, IgG, H1)		520
Cladosporium herbarum (2), - IgG (Cladosporium herbarum, IgG, M2)		520
: Penicillium notatum, Cladosporium herbarum, Aspergillus fumigatus, Candida albicans, Alternaria tenuis, IgG (MP1 (M1, M2, M3, M5, M6), Mold Panel 1: Penicillium notatum, Cladosporium herbarum, Aspergillus fumigatus, Candida albicans, Alternaria tenuis, IgG)*		950
Penicillium notatum (1), - IgG (Penicillium notatum, IgG, M1)		520
Dermatophagoides microceras (D3), - IgG (Dermatophagoides microceras, IgG, D3)		520
Dermatophagoides pteronyssinus (D1), - IgG (Dermatophagoides pteronyssinus, IgG, D1)		520
Alternaria tenuis (6), - IgG (Alternaria tenuis, IgG, M6)		520
:		
(AZF-) ((Impairment of Spermatogenesis: Full Panel (AZF-Region) (without Description))		9290
: (F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD) ((Want to Become a Mother: Pregnancy Complications (Genes F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD) (without Description))		15700
, CYP21A2, . . (Gene CYP21OHB, Freq. Mut.)		9790
: (F2, F5) (Thrombotic Tendency in Pregnancy: Minimum (Genes F2, F5))		2730
(AR, CFTR; AZF-) (Genetic Factors of Male Infertility (Genes AR, CFTR; AZF-Region))		16420
(MTHFR, MTRR, MTR) (Isolated Malformations in Fetus (Genes MTHFR, MTRR, MTR))		5280
: (F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD) (Want to Become a Mother: Pregnancy Complications (Genes F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD))		18180
(MTHFR, MTRR, MTR, F2, F5) ((Habitual Miscarriage, Thrombotic Tendency in Pregnancy: Extended Panel (Genes MTHFR, MTRR, MTR, F2, F5) (without Description))		7180
- (F2, F5) ((Thrombotic Complications of Ovulation Induction (Genes F2, F5) (without Description))		2450

(MTHFR, MTRR, MTR) (MTHFR, MTRR, MTR) (without Description))	(Isolated Malformations in Fetus (Genes MTHFR, MTRR, MTR) (without Description))	4730
(ACE, AGT, MTHFR, MTRR, MTR, F2, F5) (Gestosis and Placental Insufficiency (Genes ACE, AGT, MTHFR, MTRR, MTR, F2, F5))	(ACE, AGT, MTHFR, MTRR, MTR, F2, F5) (Gestosis and Placental Insufficiency (Genes ACE, AGT, MTHFR, MTRR, MTR, F2, F5))	10610
(F2, F5) (Thrombotic Complications of Ovulation Induction (Genes F2, F5))	(F2, F5) (Thrombotic Complications of Ovulation Induction (Genes F2, F5))	2730
(F2, F5) (Thrombotic Tendency in Pregnancy: Minimum (Genes F2, F5) (without Description))	(F2, F5) (Thrombotic Tendency in Pregnancy: Minimum (Genes F2, F5) (without Description))	2450
(MTHFR, MTRR, MTR, F2, F5) (Habitual Miscarriage, Thrombotic Tendency in Pregnancy: Extended Panel (Genes MTHFR, MTRR, MTR, F2, F5))	(MTHFR, MTRR, MTR, F2, F5) (Habitual Miscarriage, Thrombotic Tendency in Pregnancy: Extended Panel (Genes MTHFR, MTRR, MTR, F2, F5))	8010
(ACE, AGT, MTHFR, MTRR, MTR, F2, F5) (MTHFR, MTRR, MTR, F2, F5) (without Description))	(ACE, AGT, MTHFR, MTRR, MTR, F2, F5) (MTHFR, MTRR, MTR, F2, F5) (without Description))	9440
/ BRCA1, BRCA2, CHEK2, NBS1 (Hereditary Breast and/or Ovarian Cancer)	/ BRCA1, BRCA2, CHEK2, NBS1 (Hereditary Breast and/or Ovarian Cancer)	9350
(Examination of Sputum)	(Examination of Sputum)	750
Secrets)	(Examination of Transudates, Exudates, Secrets)	480
Bronchial Washouts)	(Examination of Bronchial Washouts)	590
(Examination of Punctates: Skin)	(Examination of Punctates: Skin)	590
(Examination of Endoscopic Material)	(Examination of Endoscopic Material)	590
A08.20.004	A08.20.004	600
Helicobacter pylori (Examination of Endoscopic Material: Presence of Helicobacter pylori)	Helicobacter pylori (Examination of Endoscopic Material: Presence of Helicobacter pylori)	710
(Cytological Examination of Material Obtained during Surgical Procedures and Other Urgent Research)	(Cytological Examination of Material Obtained during Surgical Procedures and Other Urgent Research)	750
(ThinPrep ®)*	(ThinPrep ®)*	1200
(The Bethesda System ? TBS) (Cytological Examination of Cervical Epithelium with Description on The Bethesda System, TBS)	(The Bethesda System ? TBS) (Cytological Examination of Cervical Epithelium with Description on The Bethesda System, TBS)	570
() (Cytological Examination: Scrapings (Smear) of Nasal Mucous Membrane (1 Localization))	() (Cytological Examination: Scrapings (Smear) of Nasal Mucous Membrane (1 Localization))	710
(Examination of Breast Discharge)	(Examination of Breast Discharge)	480
(Examination of Punctates: Other Organs and Tissues)	(Examination of Punctates: Other Organs and Tissues)	750
() (Examination of Imprint Intrauterine Device, IUD)	() (Examination of Imprint Intrauterine Device, IUD)	510
(Examination of Punctates: Breast)	(Examination of Punctates: Breast)	590
(Examination of Scrapings and Prints Tumor and Tumor Like Formations)	(Examination of Scrapings and Prints Tumor and Tumor Like Formations)	590
(Examination of Urine)	(Examination of Urine)	480
(The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), Fine-Needle Aspiration (FNA))	(The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), Fine-Needle Aspiration (FNA))	570
(Examination of Scrapings and Prints of Skin and Mucous Membranes)	(Examination of Scrapings and Prints of Skin and Mucous Membranes)	390
(Examination of Scrapings: Cervix and Cervical Canal)	(Examination of Scrapings: Cervix and Cervical Canal)	570
Ig (nti-Measles IgM)	Ig (nti-Measles IgM)	710
IgG (nti-Measles IgG)	IgG (nti-Measles IgG)	800
IgG (Anti-Tick-borne Encephalitis Virus (TBEV))	IgG (Anti-Tick-borne Encephalitis Virus (TBEV))	480

(Detection of pathogen DNA/RNA in ticks: Tick-borne encephalitis Virus (TBEV), Borrelia burgdorferi s. l., Anaplasma Phagocytophillum, Ehrlichia muris/chaffe nsis (RNA/DNA), PCR)		3360
IgM (Anti-Tick-borne Encephalitis Virus (TBEV))		610
/ « »		
(HPLC-MS/MS Organic Acids (Succinylate))		3590
HADHA (HADHA Gene, Freq. Mut. (Long-Chain 3-Hydroxyacyl-Coa Dehydrogenase (LCHAD) Deficiency))		5010
e « » (Newborn Screening "HEEL")*		4990
(Biotin-Dependent Carboxylases Activity (Biotinidase Deficiency))		5010
GCDH (1) (GCDH (Glutaryl-CoA Dehydrogenase) Gene, Freq. Mut. (Glutaric Aciduria, Type 1))		5010
(/) (Analysis of the spectrum of organic urine acids by gas chromatography with mass spectrometry (GC / MS))		8300
ASS (ASS Gene, Freq. Mut. (Citrullinemia))		9530
GCDH (1) (GCDH (Glutaryl-CoA Dehydrogenase) Gene (Glutaric Aciduria, Type 1))		40400
ACADM (ACADM Gene, Freq. Mut. (Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency))		5010
FAH (I) (FAH Gene, Freq. Mut. (Tyrosinemia, Type 1))		8340
BTD (BTD (Biotinidase Deficiency) Gene, Freq. Mut.)		5010
FAH (I) (FAH Gene (Tyrosinemia, Type 1))		49900
(TC Gene (Ornithine Transcarbamylase (OTC) Deficiency))		38030
(, Escherichia coli)		
(Escherichia coli O157:H7,), (Escherichia coli O157:H7 Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)		1100
(Escherichia coli O157:H7,), (Escherichia coli O157:H7 Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		930
(Escherichia coli O157:H7,), (Escherichia coli O157:H7. One Step Rapid Immun hromotographic Assay)		930
1, (Human		
immunodeficiency virus, quality, RNA)		2470
19,		330
- RHD (RHD gene of the fetus in the mother's blood)		5550
19,		330
19,		330
(Legionella pneumophila, One		
step rapid immun hromotographic assay, antigen, urinae)		1440
(Respiratory Syncytial Virus, RSV, One step rapid immun hromotographic assay, antigen)		930
(Hexagon Chlamydia, One step rapid immun hromotographic assay, antigen)		1020
(Neisseria gonorrhoeae test, One step rapid immun hromotographic assay)		860
(Campylobacter spp., One step rapid immun hromotographic assay, antigen, stool)		1040

(Norwalk virus) - assay, antigen, stool)	(Norwalk virus GI, GII, One step rapid immunochromatographic assay, antigen, stool)	1750
One step rapid immunochromatographic assay, antigen, urine)	(Streptococcus pneumoniae,	1440
immunochromatographic assay, antigen, stool)	(Enterovirus, One step rapid	1090
IgG -3 (Desmoglein 3, DSG3 Antibodies, IgG)		2160
IgG BP230 (Anti-Bp230 antibodies, Bullous Pemphigoid (230 kDa) Antibodies, Antibodies to BP Antigen 1, IgG)		2160
IgG BP180 (Anti-Bp180 antibodies, Bullous Pemphigoid (180 kDa) Antibodies, Antibodies to BP Antigen 2, IgG)		2160
IgG (Desmoglein Antibodies, Desmoglein 1, DSG1 and Desmoglein 3, DSG3 Antibodies, IgG)		2160
, IgG (Basement membrane zone antibodies, IgG)		2020
IgG -1 (Desmoglein 1, DSG1 Antibodies, IgG)		2160
A IgA Helicobacter pylori (Anti-Helicobacter pylori IgA)		700
A IgG Helicobacter pylori, (Anti-Helicobacter pylori IgG, Immunoblot)		3070
A IgA Helicobacter pylori, (Anti-Helicobacter pylori IgA, Immunoblot)		3070
A IgG Helicobacter pylori (Anti-Helicobacter pylori IgG)		490
1303HEL ?? - Helicobacter pylori	(?? - , 13C-Urea Breath test, UBT).	2180
A IgM Helicobacter pylori (Anti-Helicobacter pylori IgM)		700
Sputum)*	(Mycobacterium tuberculosis, DNA,	590
tuberculosis, DNA, Synovial Fluid)*	(Mycobacterium	460
tuberculosis, DNA, Cerebrospinal Fluid)*	(Mycobacterium	250
Exudate)*	(Mycobacterium tuberculosis, DNA,	250
tuberculosis, DNA, Prostatic Fluid, Semen)*	(Mycobacterium	250
IgM, IgA, IgG Mycobacterium tuberculosis, (Anti-Mycobacterium tuberculosis IgM, IgA, IgG, total)		1630
Urine)*	(Mycobacterium tuberculosis, DNA,	250
DNA, Serum)*	(Mycobacterium tuberculosis,	390
tuberculosis, DNA, Menstrual Blood)*	(Mycobacterium	250
Total)	() (Circulating Immune Complexes (CIC)	1080
	(Phagocytic Activity of Leucocytes)	1000
	(Lymphocyte Activation Ability)	3450
CD4+ - Absolute)	(- , CD4+ T-cells, Percent and	1370
CD3+ HLA-DR+, CD3-HLA DR+)*	(CD3+ HLA-DR+, CD3-HLA DR+) (Activated Lymphocyte:	1370
- , %	(CD19+ , B-cells, Percent and Absolute)	1370
(Lymphocyte Phenotyping: CD3, CD4, CD8, CD19, CD16, CD56)	() - CD3, CD4, CD8, CD19, CD16, CD56	3450
G (IgG1, IgG2, IgG3, IgG4)		12510
Virus IgM, Anti-VZV IgM)	(Anti-Varicella-Zoster	780

Varicella-Zoster, (Varicella ZosterVirus, DNA, serum)	360
IgG (Anti-Varicella-Zoster Virus IgG, Anti-VZV IgG)	710
Varicella-Zoster, (Varicella Zoster Virus, DNA, scrape of faucial epithelial cells)	360
Varicella-Zoster, (VaricellaZosterVirus, DNA, saliva)	360
(Stool Culture, Salmonella s p., Shigella s p. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)	1150
Shigella flexneri 1-5 (Shigella flexneri 1-5, IHA)	440
(Stool Culture (Salmonella spp., Shigella spp.). Bacteria Identification)	780
Shigella sonnei (Shigella sonnei, IHA)	440
(Stool Culture (Salmonella spp., Shigella spp.). Bacteria Identification and Antibiotic Susceptibility Testing)	970
Shigella flexneri 6 (Shigella flexneri 6, IHA)	440
HER2/neu (HER2/neu Expression, HER2 Status, Immunohistochemical Study (Fixed Biomaterial in Paraffin Block))	4990
(P504S, AMACR), (34?E12), p63 (Prostate cancer – complex immunomorphological examination using assessment of the expression AMACR, high molecular weight cytokeratin (34?E12), p63)*	11400
(Immunohistochemical diagnosis of Lymphoproliferative diseases (Tissue Embedded in Paraffin Block))	25280
Ki-67 (MIB-1) (Ki-67 (MIB-1) Expression, Assessment of Proliferative Activity by Expression Ki-67, Immunohistochemical Study (Fixed Biomaterial in Formalin Buffer))*	5090
(CD138) (Chronic Endometritis, Identification of Plasma Cells CD138, Immunohistochemical Diagnosis (Fixed Biomaterial in Paraffin Block))	5000
(Immunohistochemical diagnosis of Lymphoproliferative diseases (Fixed Biomaterial in Formalin Buffer))*	25280
(Estrogen and Progesterone Receptors, Immunohistochemical Study (Fixed Biomaterial in Paraffin Block))	7140
: p16INK4a (Early Diagnosis Marker of Dysplasia with High Risk Malignancy: p16INK4a, Immunohistochemical Study (Fixed Biomaterial in Paraffin Block))	4430
(Immunohistochemical diagnosis in cancer metastasis of unknown primary origin (Tissue Embedded in Paraffin Block))	25280
(Estrogen and Progesterone Receptors, Immunohistochemical Study)*	6410
(P504S, AMACR), (34?E12), p63 (Prostate cancer – complex immunomorphological examination using assessment of the expression AMACR, high molecular weight cytokeratin (34?E12), p63)	11400
: p16INK4a (Early Diagnosis Marker of Dysplasia with High Risk Malignancy: p16INK4a, Immunohistochemical Study (Fixed Biomaterial in Formalin Buffer))*	4430
HER2 in situ (FISH) (Determination of HER2 Status of Tumor, Fluorescence In Situ Hybridization)	29660

Ki-67 (MIB-1) Ki-67 () (Ki-67 (MIB-1) Expression, Assessment of Proliferative Activity by Expression Ki-67, Immunohistochemical Study (Fixed Biomaterial in Paraffin Block))		5090
(CD138) () (Chronic Endometritis, Identification of Plasma Cells CD138, Immunohistochemical Diagnosis (Fixed Biomaterial in Formalin Buffer))*		5000
HER2/neu , HER2- () (HER2/neu Expression, HER2 Status, Immunohistochemical Study (Fixed Biomaterial in Formalin Buffer))*		4990
() () (Immunohistochemical diagnosis in cancer metastasis of unknown primary origin (Fixed Biomaterial in Formalin Buffer))*		25280
A09.05.065 ()		330
(T4 ,) (Total Thyroxine, TT4)		350
(3) (Free Triiodthyronine, FT3)		350
() (Anti-Thyroid Microsomal Antibodies)		500
A09.05.063 (4)		350
(- ,) (Anti- thyroid eroxidase utoantibodies, Antimicrosomal Antibodies, TPO Antibodies, TPOAb, Anti-TPO)		390
() (Thyroid-Stimulating Hormone Receptor Antibodies, TSH Receptor Antibodies, TSHRabs, TSH binding inhibitor immunoglobulin, TBII)		1400
(-) (Anti- thyroglobulin Autoantibodies, Thyroglobulin Antibodies, Tg Autoantibodies, TgAb, Anti-Tg Ab, ATG)		440
() (Thyroglobulin, TG)		630
() (Thyroid Uptake, T-Uptake, Thyroxine-Binding Capacity, TBC, Thyroxine-Binding Index, TBI, free T4 Index, FT4I)		510
(3) (Total Triiodthyronine, TT3)		350
SARS-CoV-2, (Coronavirus SARS-CoV-2 RNA detection in nasopharyngeal and oropharyngeal smear)		1390
: (Soil: Agrochemical Evaluation)*		9080
: (Soil: Comprehensive Toxicological Evaluation)*		19940
(,) (Growth Hormone, GH)		470
(,) (Adrenocorticotrophic Hormone, ACTH)		620
(1) (Somatomedin C, Insulin-like Growth Factor 1, IGF-1)		990
() (Luteinizing Hormone, LH)		350
(Macroprolactin)*		1080
(Prolactin)		350
() (Follicle Stimulating Hormone, FSH)		350
IgG (-ASGPR) (Autoantibodies Against Asialoglycoprotein Receptor, Anti-ASGPR, IgG)		1550
IgA, IgG, IgM (,), (Anti-Mitochondrial Antibodies, AMA, IgA, IgG, IgM, Total)		1380
IgG (- 2, 2-3 , Sp100, PML, gp210, LKM-1, LC-1, SLA/LP, SSA/Ro-52), (Autoimmune Disease Liver Panel: AMA-M2, M2-3E (BPO), Sp100, PML, gp210, LKM-1, LC-1, SLA/LP, SSA/Ro-52, IgG, Immunoblotting)		3320

antibody, anti-LKM, IgG+IgM+ IgA)	IgA+IgG+IgM (anti-liver kidney microsomal	1430
IgA, IgG, IgM SMA, Anti-Smooth Muscle Antibodies, ASMA, IgA, IgG, IgM, Total)	(Smooth Muscle Antibodies,	1380
1-		
IgG	(Insulin Autoantibodies, IAA, IgG)	610
Tyrosine Phosphatase Antibodies)	(IA-2) (Islet Antigen 2 Antibodies, Anti-IA2 antibodies, IA-2 Ab,	1550
Autoantibodies, ICA)	(Anti-Islet Cell Antibodies, Islet Cell	1380
Antibodies Pool, Glutamic Acid Decarboxylase-65, GAD and Insulinoma Antigen 2 (Tyrosine Phosphatase, IA2, ICA-512) Autoantibodies, Total)	GAD/IA-2, (Anti-GAD/IA2	1550
Decarboxylase Antibodies, AT-GAD, IgG)	(-GAD) (Anti-GAD Antibodies, Glutamate	1590
()		
Antibiotic Susceptibility Testing)	(Yersinia enterocolitica, (Yersinia enterocolitica, Stool Culture. Bacteria Identification and	1240
Yersinia enterocolitica	:9 (Yersinia enterocolitica O:9, IHA)	440
IgG	Yersinia enterocolitica (Anti-Yersinia enterocolitica IgG)	490
IgA	Yersinia enterocolitica (Anti-Yersinia enterocolitica IgA)	490
Yersinia enterocolitica	:3 (Yersinia enterocolitica O:3, IHA)	440
Yersinia pseudotuberculosis (Yersinia pseudotuberculosis IHA)		440
(F2, F5, MTHFR, MTR, MTRR, F13, FGB, ITGA2, ITG 3, F7, PAI-1) (Extended Study of Hemostatic System (Genes F2, F5, MTHFR, MTR, MTRR, F13, FGB, ITGA2, ITG 3, F7, PAI-1))		
-) (Platelet Fibrinogen Receptor (Gene ITGB3) (without Description))	(ITGB3) (1260
:) (Thrombosis: Advanced Panel (Genes F2, F5, MTHFR, MTRR, MTR) (without Description))	(F2, F5, MTHFR, MTRR, MTR) (7180
platelets, gene polymorphism ITGA2 .759 >T	ITGA2 .759 >T Hyperaggregation of	2760
: (F2, F5) ((F2, F5) (2450
-) (Hyperhomocysteinemia (Genes MTHFR, MTRR, MTR) (without Description))	(MTHFR, MTRR, MTR) (4730
-) Hyperaggregation of platelets, gene polymorphism ITGA2 .759 >T (without description)	ITGA2 .759 >T (2470
:	(F2, F5) (Thrombosis: Minimum (Genes F2, F5))	2730
MTRR, MTR))	(MTHFR, MTRR, MTR) (Hyperhomocysteinemia (Genes MTHFR, MTRR, MTR))	5280
: (F2, F5, MTHFR, MTRR, MTR) (Thrombosis: Advanced Panel (Genes F2, F5, MTHFR, MTRR, MTR))	(F2, F5, MTHFR, MTRR, MTR) (8010
FGB, ITGA2, ITG 3, F7, PAI-1) ((F2, F5, MTHFR, MTR, MTRR, F13, FGB, ITGA2, ITG 3, F7, PAI-1) (Extended Study of Hemostatic System (Genes F2, F5, MTHFR, MTR, MTRR, F13, FGB, ITGA2, ITG 3, F7, PAI-1) (without Description))	9450
(Listeria monocytogenes, DNA,		
Cerebrospinal Fluid)*	(Listeria monocytogenes, DNA, Urine)*	230
monocytogenes, DNA, Scrape of Nasal Epithelial Cells)*	(Listeria	210
Antibiotic Susceptibility testing)	(Listeria monocytogenes) (Listeria monocytogenes Culture. Bacteria Identification and	690
,	(Listeria monocytogenes, DNA, Plasma)*	210
monocytogenes, DNA, Scrape of Faucial Epithelial Cells)*	(Listeria	210

Fluid)*	(Listeria monocytogenes, DNA, Synovial	460
IgE:		
	, IgE (GP3 (G1, G5, G6, G12, G13), Grass Panel: Sweet Vernal Grass, Perennial Rye Grass, Timothy Grass, Cultivated Rye Grass, Velvet Grass, IgE)*	950
	, IgE (Cottonwood, IgE, T14)	440
	, IgE (Wormwood, IgE, W5)	440
	, IgE (Timothy Grass, IgE, G6)	440
	, IgE (WP1 (W1, W6, W9, W10, W11), Weed Panel: Common Ragweed, Mugwort, English Plantain, Lamb's Quarters, Russian Thistle, IgE)*	950
	, IgE (Birch, IgE, 3)	440
	, IgE (Mugwort, IgE, W6)	440
	, IgE (TP9 (T2, T4, T12, T3, T7), Tree Panel: Alder, Hazelnut, Willow, Birch, Oak, IgE)*	950
	, IgE (GP1 (G3, G4, G5, G6, G8), Grass Panel 1: Orchard Grass, Meadow Fescue, Perennial Rye Grass, Timothy Grass, June Grass (Kentucky Bluegrass), IgE)*	950
25-OH D (25-OH Vitamin D Total, 25(OH)D, 25-Hydroxycalciferol)		
	() (Deoxyypyridinolinein, DPD, Urine)	1920
	(Gla) (steocalcin, N-Osteocalcin, Bone Gla Protein, BGP)	1250
N-P1NP, Total)	1 (Procollagen Type 1 N-terminal Propeptide,	670
	(-CrossLaps, -) (Carboxyterminal Cross-linking Teloepptide of Bone Collagen, Collagen Cross-linked C-Teloepptide, Beta-Cross Laps, ?-CrossLaps Serum, C-Teloepptide, Crosslaps, Type 1 Collagen, b- Tx Serum)	1360
	(Human Cartilage Oligomeric Protein, COMP)	870
(A B)		
agalactiae),	(Streptococcus group B, Streptococcus (Streptococcus agalactiae Culture. Bacteria Identification and Antibiotic Susceptibility Testing)	880
agalactiae) (Streptococcus agalactiae Culture. Bacteria Identification)	(Streptococcus group B, Streptococcus (Streptococcus Group B. One Step Rapid Immun chromatographic Assay)	690
Step Rapid Immun chromatographic Assay)	() (Streptococcus Group A. One	1050
pyogenes),	(Streptococcus group A, Streptococcus (Streptococcus pyogenes Culture. Bacteria Identification and Antibiotic Susceptibility Testing)	870
	(Streptococcus spp., DNA, Saliva)*	810
pyogenes) (Streptococcus pyogenes Culture. Bacteria Identification)	(Streptococcus group A, Streptococcus (Streptococcus spp., DNA, Plasma)*	390
spp., DNA, Scrape of Faucial Epithelial Cells)*	(Streptococcus	620
	(Streptococcus spp., DNA, Sputum)*	590
		390
		790
(Metanephrines fractionated, free and conjugated , 24-), 24-	2260
and Serotonin Metabolites, 24 Hours-Urine: Vanillylmandelic Acid, V , Homovanillic Acid, V , 5-Hydroxyindoleacetic Acid, 5- I)	(), 5- (5-) (Catecholamines	2260
	(Serotonin, Serum)	2090
Epinephrine/Adrenaline, Norepinephrine/Noradrenaline, Dopamine, Urine)	(Catecholamines:	2060
(Catecholamines: Epinephrine/Adrenaline, Norepinephrine/Noradrenaline, Dopamine, Plasma)		2090

(Histamine, Plasma)		2420
(Metanephrines fractionated, free + conjugated, random urine)		1830
(Catecholamines: Epinephrine/Adrenaline, Norepinephrine/Noradrenaline, Dopamine, Urine)		2060
(Opisthorchis felineus)		
IgG (Anti-Opisthorchis felineus IgG)		790
(Giardia lamblia), Rapid Immunochromatographic Assay)	(Giardia lamblia. One Step	870
IgM, IgG, IgA (Anti-Giardia lamblia IgM, IgG, IgA, Total)		570
()		
(Amylase, 24-Hour or Timed Urine)		230
(Ca), (Calcium (Ca), 24-Hour urine)		200
(K), (Na), (Potassium (K), Sodium (Na), 24-Hour urine)		190
(Glomerular Filtration Rate, GFR)*		190
(Glucose, 24-Hour urine)		150
(Urea, 24-Hour urine)		150
(Uric acid, 24-Hour urine)		190
(Protein Total, 24-Hour urine)		130
(), (Magnesium, 24 h urine excretion)		300
		1890
(oxalates, 24-Hour urine)		1220
(Albumin, 24-Hour urine)		320
(Creatinine, 24-Hour urine)		150
(P), (Phosphorus (P), 24-Hour urine)		200
(Immunoglobulin A, IgA)		250
(Immunoglobulin , Ig)		250
G (Immunoglobulin G, IgG)		250
IgE Total) E (IgE,) (Immunoglobulin Total,		390
IgG (Anti-GBM, IgG)	(-) (Glomerular Basement	1560
ntibodies, ANCA, IgG)	() (Anti-Neutrophil cytoplasmic	1220
PR-3 ANCA, IgG)	-3 (-PR-3) (Anti-roteinase-3 ntibodies, PR-3- ntibodies,	1120
IgG, IgA, IgM (Anti-Phospholipase A2 Receptor Antibodies, Anti-PLA2R, IgG, IgA, IgM, Total)	2 (PLA2R),	2470
(Anti-Neutrophil Cytoplasmic Antibodies, ANCA, IgG, Panel)	(), IgG	3100
IgG C1q (Anti-Complement 1q Antibodies, Anti-C1q, IgG)		1120
IgG, IgA, IgM (Anti-Endothelial Cell Antibodies, AECA, IgG, IgA, IgM, Total)	(HUVEC),	1550
IgG (- PO) (Myeloperoxidase Antibody, MPO)		1120
1- 3- (Anti-Poliiovirus serotypes 1, 3, IgG)		1450
b, IgG (IgG (polyribosylribitolphosphate, PRP) (Haemophilus influenzae b (HiB), anti-PRP Haemophilus influenzae b IgG)		1810

()			
A	IgG	Borrelia burgdorferi (Anti-Borrelia burgdorferi IgG)	570
		(orrelia burgdorferi, DNA, Cerebrospinal Fluid)*	460
		(orrelia burgdorferi, DNA, Synovial Fluid)*	460
A	IgM	Borrelia burgdorferi, burgdorferi IgM, Western Blot (WB)) - (Anti-Borrelia	1800
A	IgG	Borrelia burgdorferi, (Anti-Borrelia burgdorferi IgG, Immunoblot)	2020
A	IgM	Borrelia burgdorferi (Anti-Borrelia burgdorferi IgM)	570
(Barbiturates, Urine)*			1120
? () (Drugs and Psychotropic Substances Screening: Opiates, Amphetamines, Methamphetamine, Cocaine, Cannabinoids, Cannabinoid Metabolites, Urine)			3100
() (Cannabinoids (Marijuana), Urine)*			1120
() (Ethanol (Alcohol) Urine)*			1120
« » (;) (Pernicious Habits: Nicotine, Drugs, Psychostimulants and Psychotropic Substances, Urine)*			3280
(/) (Opiates (Morphine/Heroin), Urine)*			1120
- (-)			
		(EBV DNA, Exudate)*	250
Fluid)*		(EBV DNA, Cerebrospinal	250
	IgG	(nti-EBV Viral Capsid	690
Antigens (VCA) IgG)		(nti-EBV Early Antigen (EA)	570
IgG)	IgG	(nti-EBV Nuclear Antigen	480
(EBNA) IgG)		(EBV DNA, Blood)*	380
		(EBV DNA, Saliva)*	250
Fluid, Semen)*		(EBV DNA, Prostatic	250
		(EBV DNA, Scrape of Nasal Epithelial Cells)*	250
		(EBV DNA, Scrape of Urogenital Epithelial Cells)*	250
	Ig	(nti-EBV Viral Capsid	480
Antigens (VCA) Ig)		(EBV	250
DNA, Scrape of Faucial Epithelial Cells)*		(EBV DNA,	370
Serum)*		(EBV DNA, Urine)*	250
		(EBV DNA, Serum)*	380
IgE:			
	2		1840
		, IgE (Pediatric Panel, IgE)	3670
	1		1840
		, IgE (Respiratory Panel, IgE)	3670
		, IgE (Panel Different Allergens, IgE)	3670
	ImmunoCAP ISAC, 112	(Allergochip ImmunoCAP ISAC, 112	27300
	llergic components)		
	ALEX2, 300	IgE	26990

(MTHFR, MTRR, MTR) (Folic Acid Metabolism (Genes MTHFR, MTRR, MTR) (without Description))		4730
: D (VDR) (Osteoporosis, Vitamin D Receptor (VDR) (Gene VDR) (without Description))		1260
(MCM6) (Adult Lactase Deficiency (Gene MCM6))		1310
, I (HFE) (Hemochromatosis Type 1 (Gene HFE))		2600
: D (VDR) (Osteoporosis, Vitamin D Receptor (VDR) (Gene VDR))		1390
(UGT1A1) (Gilbert's Syndrome (Gene UGT1A1))		4540
: (CALCR, COL1A1) (Osteoporosis: Abridged Panel (Genes CALCR, COL1A1) (without Description))		3630
- (MTHFR, MTRR, MTR) (Folic Acid Metabolism (Genes MTHFR, MTRR, MTR))		5280
: (CALCR, COL1A1) (Osteoporosis: Abridged Panel (Genes CALCR, COL1A1))		4050
: (CALCR, COL1A1, VDR) (Osteoporosis: Full Panel (Genes CALCR, COL1A1, VDR) (without Description))		4730
- HLA II (DRB1, DQA1, DQB1) (Hereditary Predisposition to Diabetes Type 1 (Insulin-Dependent Diabetes), HLA Class II (Genes DRB1, DQA1, DQB1))		6240
: (CALCR, COL1A1, VDR) (Osteoporosis: Full Panel (Genes CALCR, COL1A1, VDR))		5280
-		
123 / , 131 / , 141 / , 115 / , 124 / , 154 /) (Genetic Test Results: Description of the 2-nd Category Complexity)	2 (118 / , 121 / , 7014 , 125 / , 7207) (Genetic Test Results: Description of the 1-st Category Complexity)	1050
120 / , 137 / , 138 / , 153 / , 110 / , 114 / , 140 / , 7661 , 7258 , 134 / , 135 / , 136 /) (Genetic Test Results: Description of the 3-rd Category Complexity)	3 (122 / , 129 / , 139 / , 145 / , 108 / , 19 /) (Genetic Test Results: Description of the 4-th Category Complexity)	530
139 / , 145 / , 108 / , 19 /) (Genetic Test Results: Description of the 4-th Category Complexity)	4 (144 / , 143 / , 120 / , 137 / , 138 / , 153 / , 110 / , 114 / , 140 / , 7661 , 7258 , 134 / , 135 / , 136 /) (Genetic Test Results: Description of the 3-rd Category Complexity)	2100
139 / , 145 / , 108 / , 19 /) (Genetic Test Results: Description of the 4-th Category Complexity)	4 (144 / , 143 / , 120 / , 137 / , 138 / , 153 / , 110 / , 114 / , 140 / , 7661 , 7258 , 134 / , 135 / , 136 /) (Genetic Test Results: Description of the 3-rd Category Complexity)	4730
(4)		
(Isoprinosine)		490
(Immunomax)		490
(Immunal)		490
(Thymogen)		490
(Panavir)		490
(Tactivinum)		490
(Imunofan)		490
(Polyoxidonium)		490
(Galavit)		490
(Imunorix)		490
(Licopid)		490
()		
IgG oxoplasma gondii (nti-Toxoplasma gondii IgG)		360
Ig oxoplasma gondii (nti-Toxoplasma gondii Ig)		490
, (Toxoplasma gondii, DNA, Serum)*		380
, (Toxoplasma gondii, DNA, Cerebrospinal Fluid)*		250
Anti-Toxopl gondii IgG		950
, (Toxoplasma gondii, DNA, Exudate)*		250

pneumoniae)	(Streptococcus	450
/ Identification)	(Bordetella pertussis/parapertussis, Nasopharyngeal Culture. Bacteria	1440
(2) (Estradiol, E2)		350
(Progesterone)		350
() (Cortisol, Hydrocortisone)		350
(Free Cortisol, Free Hydrocortisone, 24-Hour urine)		690
(Aldosterone)		780
() (Direct Renin, Plasma)		830
(Cortisol, Saliva)		560
(Cystatin C)		680
A09.05.017		150
(Uric acid)		150
A09.05.020		150
- p16INK4a Ki-67		5500
(PLGF)		3600
(Inhibin B)		1120
() (Anti-Mullerian Hormone, AMH, Mullerian Inhibiting Substance, MIS)		1120
-1- () (Trophoblastic beta-1-Globulin, TBG)		440
IgG V (Annexin V antibodies, aAnV, IgG)		1190
Ig V (Annexin V antibodies, aAnV, Ig)		1190
IgG, IgA, IgM -2- 1, (Anti-?-2-Glycoprotein 1 Antibodies, anti-?-2-G 1, IgG, IgA, IgM, Total)		1140
IgM IgG (Anti-Phospholipid Antibodies, APA, IgM, IgG)		730
2 IgA		1090
IgG IgM (Anti- phosphatidylserine/ rothrombin antibodies, Anti-PS/PT, IgG, IgM, Total)		1220
IgA, IgM, IgG (Cardiolipin Antibodies IgA, IgM, IgG, aCL, Screening)		1030
IgG IgM (Anti- phosphatidylserine, IgG, IgM)		1620
2 IgM		1190
(Anti-Phospholipid Antibodies Panel)		8190
IgA (Anticardiolipin IgA, aCL IgA)		760
2 IgG		1090
IgG (Anticardiolipin IgG, aCL IgG)		820
IgM (Anticardiolipin IgM, aCL IgM)		1080
(Bile Acids)		2410
1 (1, 1) (Apolipoprotein A1, Apo A1)		520

Cholesterol) (, , VLDL	370
B (B,) (Apolipoprotein B, Apo B)	390
() (Triglycerides)	190
A09.05.004	200
(a), () (Lipoprotein (a), Lp (a))	790
A09.05.028	150
() (Cholesterol Total)	190
() Cholesterol LDL (direct)	230
(4)	
(Neovir)	490
(Amixin)	490
(Cycloferonum)	490
(Kagocel)	490
(Pregnancy-Associated Plasma Protein-A, PAPP-A)	630
(, - , ?-) (Human Chorionic Gonadotropin, HCG)	350
?- (?-) (Free Human Chorionic Gonadotropin, Free HCG)	490
PRISCA2	90
fms- -1 (sFlt-1)	3070
(Estriol Free, 3)	440
PRISCA1	120
() (Placental Lactogen, PL, Human Placental Lactogen, hPL, Chorionic Somatomammotropin, CS, Human Chorionic Somatomammotropin, hCS)	630
() (Erythrocyte Sedimentation Rate, ESR)	130
() (Leucocyte Formula (Differential White Blood Cell Count) with Manual Microscopic Examination of Blood Smear)*	300
() (Leucocyte Formula (Differential White Blood Cell Count) with Microscopic Examination of Blood Smear if Presence of Pathologic Changes)*	190
() (Platelets, Microscopy (Manual Platelet Count (PLT Count): Indirect Method by Fonio))*	250
() () (General Blood Analysis, without White Blood Cell (WBC) Count and ESR)	190
(Reticulocytes)	240
	1800
(4)	
(Ingaron)	490
(Reaferonum)	490
Bordetella species: Bordetella pertussis () Bordetella bronchiseptica () (Differentiated detection of DNA Bordetella spp.: Bordetella pertussis (pertussis pathogen) and Bordetella bronchiseptica (bronchosepticosis pathogen) in a scraping of the oropharynx and or nasopharynx)	840
A IgG Bordetella pertussis (Anti-Bordetella pertussis IgG)	810
A IgM Bordetella pertussis (Anti-Bordetella pertussis IgM)	810
A IgA Bordetella pertussis (Anti-Bordetella pertussis IgA)	810

-3	(Omega-3 Index)		4340
	(Procalcitonin)		2730
	, : -3,-6,-9, (Fatty acids panel, omega-3, -6, -9, plasma)		8340
	Rh- (Anti Rh)		470
	(Blood Group, O)		230
Rh (C, E, c, e) Kell-	(Rh C (E, c, e) Kell-Phenotyping)		600
-	(-) (Rh-factor, Rh)		230
:	(Water: Complete and Comprehensive Quality Assessment)*		18180
:	(Water: Suspicion Industrial Waste Contamination)*		12900
:	(Water: Suspicion Products of Combustion and Emissions from Motorways Contamination)*		9530
:	(Water: Suspicion Household Waste Contamination)*		8130
:	(Water: Abridged Quality Assessment)*		8790
:	(Water: Suspicion Excessive Use of Chemicals for Water Treatment)*		4690
	(, Trichinella spiralis)		
	IgG (nti-Trichinella IgG)		470
:	20 (Water: Quality Assessment 20 Parameters)*		3730
	6 (Determination of Concentration 6 Radionuclides)*		22430
?-	(Radiological Drinking Water Study – Basic Test ?- and ?-Activity)*		6170
:	30 (Water: Quality Assessment 30 Parameters)*		7060
	4 (Determination of Concentration 4 Radionuclides)*		14940
	(ACE, AGT, NOS3) (Arterial Hypertension: Full Panel (Genes ACE, AGT, NOS3))		4140
	(ACE, AGT, NOS3) ((Arterial Hypertension: Full Panel (Genes ACE, AGT, NOS3) (without Description))		3710
	(ACE, AGT) (Arterial Hypertension, Renin-Angiotensin System Disorder (Genes ACE, AGT))		2760
	(ACE, AGT) ((Arterial Hypertension, Renin-Angiotensin System Disorder (Genes ACE, AGT) (without Description))		2470
	(NOS3) ((Arterial Hypertension, Endothelial NO-Synthase Disturbance (Gene NOS3) (without Description))		1260
	() (Compositional Analysis of Urine (Kidney) Stones, infrared spectrometry)		3520
	() (Compositional Analysis of Urine (Kidney) Stones, infrared spectrometry, -ray diffraction analysis)		3520
	(Alzheimer's Disease)		2600
	- -17 () (Gastrin-17 Stimulation Test, Gastrin-17, G-17)		1100
	I (Pepsinogen I)		880

	(Gastrin)		620
	(GastroPanel)		4160
	II (Pepsinogen II)		880
G	(G, Hepatitis G Virus, HGV)	
	G,	(HGV RNA, Serum)*	600
	(FibroTest)		10860
	(FibroMax)		13880
	(FibroTest)		12200
	(SteatoScreen)		5760
	(FibroMax)		16000
	NASH-FibroTest		17550
	NASH-FibroTest ()	17120
	()	7200
	() (Karyotype)	7090
	()	16170
	(Acute Intestinal Infections, PCR, Fecal)		1430
	(Enterovirus, RNA, Fecal)		470
	(Acute Intestinal Infections, PCR, Fecal)		1130
	CYP2D6	(beta-Adrenergic Blockers, Gene CYP2D6)	7390
		ATII.	2760
	(ACE) (ACE Inhibitors, Fluvastatin, ATII Receptor Blockers.		5280
	(Methotrexatum. Genetic Markers of Increased Risk of Development of Adverse Reactions in Taking Methotrexate for Treatment of Rheumatoid Arthritis. Methotrexate Disrupts Metabolism		
A	IgG	(Anti-Mumps IgG)	710
A	IgM	(Anti-Mumps IgM)	710
	()	450
	(Streptococcus pneumoniae, DNA)		
	(Calcitonin)		860
	() (Parathyroid Hormone, PTH)	610
	(, Echinococcus spp.)	
	IgG	(Anti-Echinococcus IgG)	790
	IgG	(Anti-Entamoeba histolytica IgG)	630
D	(D, Hepatitis D Virus, HDV)	
	IgM IgG	D, o (Anti-HDV Total (IgG + IgM))	780

D,	(HDV RNA, Serum)*	600
IgM	D (anti-HDV IgM)	780
Aspergillus fumigatus (3), - IgG (Aspergillus fumigatus, IgG, M3)		
(Bacteroides spp., DNA, Scrape of Urogenital Epithelial Cells)*		
A	(, Hepatitis A Virus, HAV)	210
IgG	(Anti-HAV IgG)	510
	(HAV RNA, Serum)*	590
IgM	(Anti-HAV IgM)	730
()		
(Gardnerella vaginalis, DNA, Scrape of Urogenital Epithelial Cells)*		250
Prostatic Fluid, Semen)* (Gardnerella vaginalis, DNA,		250
(Gardnerella vaginalis, DNA, Urine)*		250
Converting Enzyme, ACE, Serum) () (Angiotensin		
()	(Neopterin, Serum)	1550
IgG	(),	1220
(Anti-Heart Antibodies, IgG)		
HOMA-G	()	50
HOMA-IR		50
(Proinsulin)		830
- (C-Peptide)		390
(Insulin)		490
Identification) (Campylobacter s p.) (Campylobacter spp., Stool Culture. Bacterial		
()		
(Rotavirus), Agglutination)	(Rotavirus Direct Detection by Latex	680
3690		
- (Varicella-Zoster)		
Varicella-Zoster, Zoster Virus, DNA, scrape of skin epithelial cells)	(Varicella	360
(-)		
(Fungal Infections of Nails)		820
(Fungal Infections of Skin)		820
IgG , (Platelet ntibodies IgG, Indirect)		
(, , , Salmonella spp.)		
Salmonella gr.A (Salmonella gr.A, IHA)		440
Salmonella gr.B (Salmonella gr.B, IHA)		440
Salmonella gr.E, (Salmonella gr.E Antibodies, IHA)		440
Salmonella typhi, (Salmonella typhi Antibodies, IHA)		560
Salmonella O- (Salmonella O-antigens, IHA)		440

Salmonella gr.D (Salmonella gr.D, IHA)		440
Salmonella gr. (Salmonella gr.C, IHA)		440
IgG	(Anti-Strongyloides stercoralis IgG)	900
	(Rickettsia prowazekii, IHA)	440
A09.05.021		150
A09.05.022		150
	Anisakis IgG	740
IgG	(Anti-Diphtheria Toxoid IgG)	900
	(Corynebacterium diphtheriae Culture)	690
	(Anti-Spermatozoa Antibodies, ASA, Semen)	1290
	(Anti-Spermatozoa Antibodies, ASA, Serum)	950
	(Anti-Hepatitis E Virus, HEV)	
IgM	E (Anti-HEV IgM)	810
IgG	E (Anti-HEV IgG)	810
IgG:		
	(2), - IgG (Dog Epithelium, IgG, E2)	520
	(1), - IgG (Cat Dander-Epithelium, IgG, E1)	520
	(Streptococcus pneumoniae, DNA)	450
IgG	(Anti-Adenovirus IgG)	710
IgA	(Anti-Adenovirus IgA)	710
	(Streptococcus pneumoniae, DNA)	450
	(Anti-Toxocara canis)	
IgG	(Anti-Toxocara IgG)	470
	(Androflor® REAL-TIME PCR Detection Kit, the study of men's urogenital tract microbiocenosis in the epithelial scrapes from the balanus, urethra)	2580
	(Androflor® Screen REAL-TIME PCR Detection Kit, the study of men's urogenital tract microbiocenosis in the epithelial scrapes from the balanus, urethra)	1810
	(DLG5, NOD2, OCTN1, OCTN2) (Crohn's Disease (Genes DLG5, NOD2, OCTN1, OCTN2))	8090
	IgA, IgM, IgG (Anti-Ovarian Antibodies, AOA, IgA, IgM, IgG, total)	1290
	IgA, IgM, IgG (Anti-Steroidal Cell Antibodies, StCAb, Steroidal Cell Autoantibodies, SCA, IgA, IgM, IgG, Total)	1120
	IgA, IgM, IgG (Anti-Testicular Steroid-ell Antibodies, Testicular Anti-Steroidal Cell Antibodies, Testicular StCAb, Steroidal Cell Autoantibodies, SCA against Testis, IgA, IgM, IgG, Total)	1550

YP2D6 (YP2D6) (Cytochrome YP2D6 (Gene YP2D6))		7390
(Neisseria meningitidis Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		850
() (Total Antioxidant Status, TAS)		4770
IgE:		
, IgE (Latex, IgG, K82)		440
IgG (Anti-Ascaris lumbricoides IgG)		880
(, Demodex folliculorum, Demodex brevis)		
(Demodex folliculorum, Demodex brevis)		340
() (Consultation of Finished Cytological Preparations (1 Glass))		380
Clonorchis sinensis IgG		980
- 8		
IgG 8 (Anti-HHV-8 IgG)		700
()		
).* (Provision of test findings in English (translation of test findings in English)).*		200
(Erythropoetin)		960
(Leptin)		760
()		
(Cryptosporidium parvum), (Cryptosporidium parvum. One Step Rapid Immunochromatographic Assay)		790
-		
IgG - 1 2 (Anti-HTLV-1, 2 IgG)		780
(Study of Interferon Status)		2450
(Assessment of Androgen Status)		1460
(Female Hormonal Profile: Ovarian Dysfunction, Menstrual Irregularities)		3300
(Female Hormonal Profile: Ovarian Dysfunction, Menstrual Irregularities)		3420
		3190
:		3520
		6410
« »		7500
« »		9060
« »		15710
-		19010
() (Acute Respiratory Infections, ARI: Runny Nose, Cough, Sore Throat)		7390
A IgA IgG Chlamydia trachomatis, (Anti-Chlamydia trachomatis IgA, IgG)		970

« : 6 () » (Comprehensive Study «Sex in City: 6 Infections (Blood Test)»)	3150
« : 6 () » (Comprehensive Study «Sex in City: 6 Infections (Blood Test)»)	3270
: (Joint Pain: Extended Survey)	6780
: (Want to Become a Mother: Pregnancy Planning, Comprehensive Survey)	6990
VIP- (VIP-Survey for Men)	7240
VIP- (VIP-Survey for Women)	14790
(Pediatric Infections: Immune Response)	15700
A IgM IgG Mycoplasma pneumoniae (Anti-Mycoplasma pneumoniae IgM, IgG)	5440
TORCH- (ToRCH-Infections)	990
: I (1-13) (Pregnancy: First Trimester (1-13 Weeks))	3240
, , (HIV, Syphilis, Hepatitis B, C)	7480
« : 8 + » (Comprehensive Study «Sex in City: 8 Infections + Smear on Flora»)	1400
: III (29-30) (Pregnancy: Third Trimester (29-30 Weeks))	2540
« : 14 + » (Comprehensive Study «Sex in City: 14 Infections + Smear on Flora»)	3630
:	4010
() (Hemostasiogram (coagulogram), extended	9930
: (Survey of Liver: Extended)	2510
(Hospitalization in Therapeutic Hospital)	2630
(Hospitalization in Surgical Hospital)	3330
: (Hospitalization in Surgical Hospital: Extended Survey)	4600
« » (My Healthy Nurse)	6720
ROMA (Risk of Ovarian Malignancy Algorithm,) () (Risk of Ovarian Malignancy Algorithm, ROMA (Before Menopause))	7020
ROMA (Risk of Ovarian Malignancy Algorithm,) () (Risk of Ovarian Malignancy Algorithm, ROMA (After Menopause))	1650
- () (Breast Cancer, Immunohistochemistry, IHC (Formalin-Fixed Biomaterial))	1650
- () (Breast Cancer, Immunohistochemistry, IHC (Paraffin-Embedded Tissue Block))	15660
- : p16INK4a + Ki-67 () (Cervical Cancer – Study of Two Markers for Early Diagnosis Dysplasia with High Risk Malignancy: p16INK4a + Ki-67, Immunohistochemical Screening (Fixed Biomaterial in Paraffin Block))	15660
- : p16INK4a + Ki-67 () (Cervical Cancer – Study of Two Markers for Early Diagnosis Dysplasia with High Risk Malignancy: p16INK4a + Ki-67, Immunohistochemical Screening (Fixed Biomaterial in Formalin Buffer))*	7830
: (Metabolic bone and osteoporosis risk evaluation: comprehensive examination).	7830
: I (PRIS A-1) (Maternal Screen, First Trimester; Prenatal Screening I; PRIS A I (Prenatal Risk Calculation))	5360
: II (PRIS A-2) (Maternal Screen, Second Trimester; Prenatal Screening II; PRISCA II (Prenatal Risk Calculation))	1170
(), (Coagulation, Gemostaziogram, Screening)	1300
: (Miscarriage: Autoimmune Profile)	770
(Immunological Survey Extended)	3640
: (Survey of Liver: Screening)	10980
	840

		1100
Supersport		2000
	(Serum Biochemistry: Minimum)	2020
Supersport		3100
	(Serum Biochemistry: Extended Profile)	3230
You ? Healthy Country: Annual Check-Up up to 40 Years of Age	(40) (Healthy	3510
Age)	(40) (Annual Check-Up after 40 Years of	4480
	(Survey Before Diet: Additional)	4690
Supersport		6830
		3690
	(Survey of Kidneys: Extended)	2000
	(Diabetes Control: Extended)	3220
	(Toxic Trace Elements, Hair)	1620
Elements, Hair)	(Toxic Trace Elements, Essential Vital	3090
	(Elemental Composition of Hair: Screening)	5400
Elements, Toxic Trace Elements, Urine)	(Essential Vital	2600
	(Toxic Trace Elements, Nails)	1620
Elements, Nails)	(Toxic Trace Elements, Essential Vital	3090
	(Elemental Composition of Nails: Screening)	5400
		24050
		24050
		24050
		24050
		24050
		24050
		33000
	(Testing for Kindergarten and School)	1580
	0 14 (Healthy Child: for Children from 0 to 14 Years)	660
	(Survey of Kidneys: Screening)	870
		890
		18500
		17400
		17400
	(Panel Chronic myelogenous leukemia, CML)	11900
		33000
		11100
		3150
		2210
	(, ())	2160
	()	2160
	(, (),	2250
	(/pANCA, cANCA), IgG)	2890
	(, , IgG, IgM)	3730
IgG)	(, (),	
	(/pANCA, cANCA),	

, Ig ; () , IgG;	3950
, IgG, IgM; -2- 1) (;	3970
: (Arthralgia: screening test)	4620
(Autoimmune Liver Disease: Screening)	6380
(Rheumatic arthritises)	1670
SARS-CoV-2, IgM () IgG (Anti-SARS-CoV-2, IgM/IgG)	1690
« » (Bullous Dermatitis Diagnostics profile (antibodies to epidermis desmosomes, antibodies to skin basal membrane))	3970
SARS-CoV-2, IgM IgG (Abbott)	1290
SARS-CoV-2, IgM () IgG (Anti-SARS-CoV-2, IgM/IgG)	1690
: (Thyroid Gland: Extended Survey)	1690
: (Thyroid Gland: Extended Survey)	1760
: (Thyroid Gland: Screening)	1010
: (Diabetes: Autoimmune Markers)	3560
(Rheumatoid arthritis).	2810
Ig IgG Mycoplasma hominis (Anti-Mycoplasma hominis Ig , IgG)	830
(/pANCA, cANCA), IgG)	2640
;)	2730
4 « » (Systemic lupus erythematosus (SLE) profile, activity monitoring (anti-double-stranded DNA IgG, C3 and C4 complement components))	1220
, IgG; IgA) (, IgA;	1970
Intolerance) : () (Coeliac Disease: Gluten	5660
, IgG, IgM	1800
APS) (), (Antiphospholipid Syndrome,	3570
cANCA, IgG; /ANCA, IgA; ASCA, IgG, IgA) () (/pANCA,	4340
((),)	2470
IgA, IgG; IgA) (, IgA;	3230
steroid-producing cells Antibodies) (Reproductive tissue	2690
(Food Allergy)	8150
: (Lipid Profile: Extended)	2640
: (Lipid Profile: Extended)	2640
" / " IgE, ImmunoCAP	4510
" " IgE, ImmunoCAP	4510
(NOS3) (Arterial Hypertension, Endothelial NO-Synthase Disturbance (Gene NOS3))	1390
" / " IgE, ImmunoCAP	4510
« :12 + () » (Comprehensive Study «Sex in City: 12 Infections (Urogenital Scraping)»)	2630
	1290
-	1460
*	4100
	11760

	720
(Diagnosis of Anemia)	2890
(Diagnosis of Anemia)	3200
(Preventing Heart and Blood Vessel Diseases)	2820
(Pregnancy Planning: Diagnosis of Urogenital Tract Infection (UTI))	2260
(Diabetes Control: Screening)	560
(Survey Before Diet: Minimum)	1560
(Weight Problems: Primary Survey)	2930
(Healthy skin beauty)	1260
	590
HOMA-IR (Insulin Resistance: Fasting Glucose/Insulin, Homeostasis Model Assessment of Insulin Resistance, HOMA-IR)	670
	860
(Weight Problems: Metabolic Syndrome (Primary Identification, Screening))	
(Diagnosis of Osteoporosis)	2770
(Women's Oncorisk: Cervix)	1800
(Allergy to Animals, Dust, Mold)	5780
	1500
(Strong hair and nails, velvet skin)	3150
(Trace Elements, Serum, Venous Blood: Screening)	3070
(Mold Allergy)	2010
(Plant Allergy)	4380
(Immunological Survey, Screening)	6400
(Male Sterility (Genes AR, CFTR; AZF-Region; Karyotype))	21360
(Female Infertility, Pregnancy Complication (Genes F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD, HLA II; Karyotype))	25940
(Toxic Trace Elements, Toxic Heavy Metals, Venous Blood)	1250
	2150
	2040
	160
(Estimated Glomerular Filtration Rate, eGFR, CKD-EPI Creatinine Equation)	160
	420
(Pregnancy: Second Trimester (14-28 Weeks))	760
(Clinical Blood Analysis: General Blood Analysis, Leucocyte Formula, ESR (with Manual Microscopic Examination of Blood Smear))	590
(Essential Vital Elements, Essential Trace Elements, Serum)	1250
(AZF) (Spermatogenesis disorders (6 AZF))	4610
(AZF-) (Impairment of Spermatogenesis: Full Panel (AZF-Region))	10370
	5300

(DQA1, DQB1)	HLA II	6240
-	(RH factor Genotype)	9910
(skin)	() (Parasitic Fungi, Microscopy and Culture)	1570
(nails)	() (Parasitic Fungi, Microscopy and Culture)	1570
I II	(I/ II) (Pepsinogen	1820
I/Pepsinogen II, PG1/PG2)		5880
	: sFit-1, PIGF, sFit-1/PIGF	1350
	(Mycoplasma hominis Culture, Ureaplasma spp. Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	870
:	(Male oncologic risk: prostate)	1280
-	(Aldosterone-Renin Ratio, ARR)	720
	3, 4 (Complement components C3, C4)	2120
"	", IgE, ImmunoCAP	700
:	(Lipid Profile: Screening)	1390
	(ITGB3) (Platelet Fibrinogen Receptor (Gene ITGB3))	700
:	(Lipid Profile: Screening)	720
	CKD-EPI – (Estimated Glomerular	
Filtration Rate, eGFR, CKD-EPI ystatin C Equation)		4830
TREC KREC		
19.1	29 28.01.2021 . .	10500
() . 5.1; . 5.2; . 19.1	29 28.01.2021 .	15000
(, 40) . 5.1; . 5.2; . 19.1	29 28.01.2021 .	12070
(, 40) . 5.1; . 5.2; . 19.1	29 28.01.2021 .	11570
/		2000
(10)		230
125 (40)		440
()		580
()		150
()		150
()		450
()		950
		775.84
		950
		1800
()		1000
		1500
()		2000
		2100
(40)		100

()
()
()
()

273.29
172.59
143.14
287.54
2120
1013.34
2120
1500
700
800
1500
2600
2600
3100
3100
4000
3500